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Abstract 
 
Hepatocellular carcinoma (HCC) is the third most-common cause of cancer-related death 
worldwide. Most cases of HCC develop in patients that already have liver cirrhosis and have 
been recommended for surveillance for an early onset of HCC. Cirrhosis is the final common 
pathway for several etiologies of liver disease, including hepatitis B and C, alcohol, and 
increasingly non-alcoholic fatty liver disease. Only 20-30% of patients with HCC are eligible for 
curative therapy due primarily to inadequate early-detection strategies. Reliable, accurate 
biomarkers for HCC early detection provide the highest likelihood of curative therapy and 
survival; however, current early-detection methods that use abdominal ultrasound and serum 
alpha fetoprotein are inadequate due to poor adherence and limited sensitivity and specificity. 
There is an urgent need for convenient and highly accurate validated biomarkers for HCC early 
detection. The theme of this review is the development of new methods to discover 
glycoprotein-based markers for detection of HCC with mass spectrometry approaches. We 
outline the non-mass spectrometry based methods that have been used to discover HCC 
markers including immunoassays, capillary electrophoresis, 2-D gel electrophoresis, and lectin-
FLISA assays. We describe the development and results of mass spectrometry-based assays 
for glycan screening based on either MALDI-MS or ESI analysis. These analyses might be 
based on the glycan content of serum or on glycan screening for target molecules from serum. 
We describe some of the specific markers that have been developed as a result, including for 
proteins such as Haptoglobin, Hemopexin, Kininogen, and others. We discuss the potential role 
for other technologies, including PGC chromatography and ion mobility, to separate isoforms of 
glycan markers. Analyses of glycopeptides based on new technologies and innovative 
softwares are described and also their potential role in discovery of markers of HCC. These 
technologies include new fragmentation methods such as EThcD and stepped HCD, which can 
identify large numbers of glycopeptide structures from serum. The key role of lectin extraction in 
various assays for intact glycopeptides or their truncated versions is also described, where 
various core-fucosylated and hyperfucosylated glycopeptides have been identified as potential 
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markers of HCC. Finally, we describe the role of LC-MRMs or lectin-FLISA MRMs as a means 
to validate these glycoprotein markers from patient samples. These technological 
advancements in mass spectrometry have the potential to lead to novel biomarkers to improve 
the early detection of HCC. 
 
Keywords: Cancer, Hepatocellular Carcinoma, Biomarkers, Early Detection, Lectins, Glycans, 
Glycopeptides, Fucosylation, MALDI-MS, ESI-MS 
 
I. Introduction 
Hepatocellular carcinoma (HCC) is the third most-common cause of cancer-related death 
worldwide (Perz et al., 2006;Kanwal et al., 2011;El-Serag, 2012;White et al., 2017). The primary 
risk factors for development of cirrhosis are chronic hepatitis B (HBV) infection and presence of 
hepatic cirrhosis from any cause (e.g., hepatitis C (HCV), alcohol (ALD), non-alcoholic fatty liver 
disease (NAFLD)) (Table 1). Because patients with cirrhosis have a 2-8% annual risk to 
develop HCC, they are recommended to undergo surveillance for HCC with abdominal 
ultrasounds every 6 months (Kanwal et al., 2011;El-Serag, 2012). In the U.S., Europe, and 
Japan, ˂ 30% of the patients are diagnosed with HCC at an early stage which would result in a 
5-year survival rate near 70%, whereas patients diagnosed at later stages have a 2-year 
survival rate ˂ 16% (White et al., 2017). HCC is increasing in incidence in many countries 
worldwide and is responsible for over 700,000 deaths per year globally. Thus, early detection of 
HCC and the ability to distinguish early HCC from patients being monitored for cirrhosis is 
critical for patient survival and this is best achieved through reliable surveillance testing in 
patients with cirrhosis. 
Table 1. Risk factors for Cirrhosis and Subsequent Hepatocellular Carcinoma 
Risk factors 
Annual risk for HCC with cirrhosis 
(Bruix et al., 2011;Ioannou et al., 
2018;Kanwal et al., 2018) 
Hepatitis C (HCV) 3-5% 
Hepatitis B (HBV) 3-8% 
Alcoholic liver disease (ALD)  0.8%-1.0% 
Non-alcoholic fatty liver disease (NAFLD) 0.9%-1.1% 
Other Etiologies Cirrhosis 1.0% 
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The risk of HCC development depends on several different factors that vary depending on 
geography and demographic factors. HBV infection is the most-common etiologic factor to 
develop HCC and is associated with ˃ 80% of the HCC cases worldwide. There are more than 
350 million people that are chronically infected with HBV globally, with the largest number in 
East Asia. Chronic hepatitis C infection is the most-common etiologic agent that leads to 
cirrhosis and HCC in many Western countries and the United States. The prevalence of 
cirrhosis has increased over the past 20 years, largely due to the prevalence of hepatitis C in 
the baby boomer population and the emergence of NAFLD-related liver disease which has 
resulted in steady increases in the incidence of HCC. 
Only about 20-30% of patients with HCC are eligible for curative therapy with surgical 
resection, liver transplantation, or local ablative procedures (Bruix et al., 2005). Liver 
transplantation can cure HCC and the underlying liver disease; however, it is limited by recipient 
selection and organ availability. Surgical resection and local ablative therapies, although 
potentially curative, can only be applied to a minority of patients. The goal to development of 
new biomarkers for HCC detection is to increase the proportion of patients diagnosed at an 
early stage that would be eligible for such curative therapies.  
The most-common non-invasive detection of HCC involves imaging, including ultrasound, 
computer tomography, and magnetic resonance imaging (Trevisani et al., 2001). Ultrasound is 
often used to detect small masses at an early stage in the liver but requires at least a 2 cm 
mass and often is not effective for early-stage detection. However, the American Association for 
the study of Liver Diseases guidelines recommends that surveillance for HCC be performed with 
ultrasonography at 6- to 12-month intervals. MRI is an effective method of detection, but the 
cost is excessive for routine screening. Serum biomarkers are often used together with these 
imaging techniques to improve the sensitivity for early detection of HCC (Marrero and Henley, 
2011). 
Serum biomarkers are used as a complementary method for early detection in patients with 
cirrhosis (Marrero and Henley, 2011;Singal et al., 2012). Serum alpha-fetoprotein (AFP) is the 
most widely used as a clinical HCC diagnostic marker; however, detection of AFP suffers from 
low sensitivity. The receiver operating characteristic curve (ROC), a plot of the data pairs for 
sensitivity and 1–specificity, and the area under the curve (AUC) (Hanley and McNeil, 1982) 
have been widely used for the assessment of diagnostic ability of biomarkers. One study has 
shown that AFP has a specificity of 90.6% and a sensitivity of 60.0% at the cut-off value of 20 
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ng/mL (Flores and Marrero, 2014). AFP accuracy in HCC early detection varies by etiology of 
disease. The performance of AFP to differentiate cirrhosis versus HCC in patients with HCV is 
only an AUC of 0.64 whereas the AUC to differentiate HBV-related HCC from HBV-related 
cirrhosis is 0.9. 
Des-gamma carboxy prothrombin (DCP) has been widely used as an alternative marker for 
AFP in Japan. However, the diagnostic value of DCP varies depending on the underlying 
characteristics of the patients (Marrero et al., 2009). AFP-L3 has also been used as a marker, 
but has not been shown to add significantly to the sensitivity for early detection of HCC (Marrero 
et al., 2009). All these markers still have relatively low sensitivity for early HCC detection, and 
current guidelines do not recommend their routine use in HCC surveillance. In any case, serum 
markers are urgently needed to enhance the sensitivity of HCC early detection over the 
currently available tests in order to increase the number of patients eligible for curative 
therapies. 
Glycosylation has been associated with a majority of cancer serum biomarkers. Most prior 
work though has involved monitoring changes in the protein level rather than any distinctive 
changes in the actual glycan structure. However, new developments in mass spectrometry 
based technology and informatics have allowed the detailed study of glycan structure and site 
specificity. These developments have been applied to studies of glycoproteins in patient serum 
where it has been shown that changes in the structures of glycans on specific sites in a protein 
may provide potential markers for monitoring changes in disease state and as markers for early 
detection of cancer. Such work has been demonstrated in several different cancers but 
particular progress in this area has been made in the case of HCC where glycan and 
glycopeptide markers have been identified which can provide early detection for the 
development of HCC from patients being monitored for cirrhosis (Zhu et al., 2014;Yin et al., 
2015). 
In the current review we discuss developments in state of the art methods to find new 
glycoprotein markers for early detection of HCC and the ability to distinguish HCC from cirrhosis 
based on changes in glycan structures identified via novel mass spectrometry techniques. 
These markers would be used for early detection of HCC, which includes screening and 
surveillance of potential patients at risk with cirrhosis or other liver diseases or as a diagnostic 
tool to differentiate patients with cirrhosis from those who have developed HCC. However, there 
are other uses for many of these markers, which include markers to stratify at-risk populations, 
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stratify patients for clinical trials, and to predict treatment response to therapies. Some of the 
markers that might prove ineffective for early detection might prove valuable for these other 
purposes. 
This article will cover various methodologies that have been used for biomarker 
glycoprotein analysis in the context of early detection of HCC, and will include methods for 
glycan- and glycopeptide-based assays. Methods to be covered include mass spectrometric 
analysis of glycans and glycopeptides using both targeted and untargeted techniques, 
strategies to enrich glycopeptides and glycoproteins from biological fluids, microarray assays, 
and gel-based methods of analysis and separation methods that can separate glycans and 
glycopeptides including isomeric forms of these units. The applications of these methods to 
important biomarker discoveries for liquid biopsies in serum for HCC will be discussed including 
efforts to validate some of these markers. 
 
II. Glycosylation 
Glycosylation is the most-frequent and important post-translational modification (PTM) of 
proteins, which has been demonstrated to participate in many key pathological steps during 
tumor development and progression (Fuster and Esko, 2005;Miyoshi et al., 2008;Pinho and 
Reis, 2015). Aberrant glycosylation is highly associated with the development of HCC, where 
increased fucosylation, sialylation, and branching structures have been determined in target 
serum proteins or total serum glycan analysis between HCC and liver cirrhosis patients (Mehta 
et al., 2015). These cancer-related alterations in glycosylation are, therefore, valuable sources 
of biomarkers for HCC (Miyoshi et al., 2012). We provide a brief overview of the rationale for 
glycosylation as a marker of cancer, different types of glycosylation, and methods to 
isolate/purify glycoproteins and their glycans/glycopeptides applied in glyco-marker studies for 
HCC.  
a. Rationale for Glycosylation as a Marker of Cancer 
Accumulating evidence has documented that alterations in the glycosylation patterns of cell 
surface and secreted glycoproteins are directly associated with malignant transformation and 
cancer progression (Dube and Bertozzi, 2005;Meany and Chan, 2011;Pinho and Reis, 2015). A 
recent review by Munkley and Elliott has elucidated in detail that aberrant glycosylation is not 
only itself a hallmark of cancer but also enables acquisition of all other recognized hallmarks of 
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cancer (Munkley and Elliott, 2016). Aberrant glycosylation is a hallmark of many types of 
cancer, which indicates its clinical significance for cancer diagnosis, monitoring, and prognosis 
(Dube and Bertozzi, 2005;Meany and Chan, 2011;Kailemia et al., 2017). In the case of HCC, 
fucosylation levels in normal liver are relatively low, but distinctly increase during carcinogenesis 
(Miyoshi et al., 2008). The first notable glycosylation change identified as a more- specific 
marker for HCC was the α1-6 fucosylated (core-fucosylated) structure in serum AFP (Li et al., 
2001). Subsequently, elevated levels of fucosylation in other serum proteins, such as alpha-1 
anti-trypsin, alpha-1 acid glycoprotein, haptoglobin, fetuin, and transferrin were found in HCC 
patients. Increased fucosylated proteins in sera of patients with HCC originate from changes in 
fucosylation states in the liver and present a promising marker for cancer diagnosis (Mehta and 
Block, 2008;Miyoshi et al., 2012). 
b. Different Types of Glycosylation 
With glycans (also known as oligosaccharides) covalently attached to proteins at specific amino 
acid residues, glycosylation can be classified into two main categories: 1) N-glycosylation, 
linked to the amide group of asparagine (Asn) residues in the consensus sequence of N-X-S/T, 
where X can be any amino acid except proline; and 2) O-glycosylation, linked to the hydroxyl 
group of serine (Ser) or threonine (Thr) residues. In humans, glycans are assembled from ten 
monosaccharides: mannose (Man), galactose (Gal), glucose (Glc), N-acetylglucosamine 
(GlcNAc), N-acetyl-galactosamine (GalNAc), sialic acid (Neu5Ac), fucose (Fuc), glucuronic acid 
(GlcA), iduronic acid (IdoA), and xylose (Xyl) (Stowell et al., 2015). According to the Swiss-Prot 
database, the majority of serum proteins are glycosylated, whereas about 90% of glycoproteins 
carry either N-linked glycans alone or N- and O-linked ones, and 10% carry O-linked glycans 
(Apweiler et al., 1999). N-linked glycans contain a conserved GlcNAc2Man3 core structure and 
several branches, whereas O-linked glycans are usually short, and contain one to four 
oligosaccharides. Due to the immense complexity and diversity of glycan structures, such as 
composition heterogeneity, branching, differences in linkages (1–3 versus 1–4, etc.), and the 
different glycosylation sites within a protein, the characterization of glycome/glycoproteome is 
far more challenging than that of the proteome.  
III. Current Markers  
There has been a marked advance in the discovery of HCC biomarkers over the last ten years. 
Alpha-fetoprotein (Marrero et al., 2009), which can typically be monitored through a validated 
immunoassay, has been the standard biomarker for HCC and is the only FDA-approved marker 
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for diagnosis. DCP (Marrero et al., 2009), also known as PIVKA-II, is also a popular alternative 
in East Asia for HCC detection (Yamamoto et al., 2010). Although these pre-approved clinical 
markers remain under research to improve the sensitivity and specificity of their use, several 
proteins have been studied as potential candidates to improve early detection, among which 
haptoglobin and GP73 (GOLPH2) are the closest to clinical advancement. In Table 2 are shown 
the currently used markers for early HCC detection with their performance in terms of the AUC 
and the sensitivity and specificity as determined by Marrero and coworkers (Marrero et al., 
2005;Marrero et al., 2009). Several other proteins such as A1AT (Comunale et al., 2010), Apo-J 
(Comunale et al., 2011), kininogen (Wang et al., 2009), HGF (Liu et al., 2010), and hemopexin 
(Benicky et al., 2014) have shown differential expression between HCC and cirrhosis. Further 
research on these markers is needed where some, such as hemopexin, have been 
demonstrated to confer only marginally better results than AFP (Kobayashi et al., 2012). More 
recently, fucosylated kininogen has been shown to have great potential as a marker in 
combination with other clinical variables (Wang et al., 2017). Only GP73 has undergone a multi-
center epidemiological study to determine real-world sensitivity and specificity values (Mao et 
al., 2010).  
Table 2. Diagnostic performance of current markers for early HCC detection 
Early Detection Symbol Name AUC Sensitivity Specificity Reference 
AFP Alpha-fetoprotein 0.8 53 90 (Marrero et 
al., 2009) 
DCP Des-gamma carboxy 
prothrombin 
0.72 61 70 (Marrero et 
al., 2009) 
AFP-L3 Alpha-fetoprotein (binds 
to LCA) 
0.66 28 97 (Marrero et 
al., 2009) 
GP73 Golgi protein 73 0.77 62 88 (Marrero et 
al., 2005)
 
AFP + DCP  0.83 78 62 (Marrero et 
al., 2009) 
 
Laboratory methods for protein biomarker discovery have involved quantitation through 
traditional methods such as ELISA, Western blots, microarrays, and immunoblotting. Cancer-
related glyco-markers have also been extensively explored because aberrant glycosylation is 
recognized as a hallmark in oncogenic transformation (Fuster and Esko, 2005). More recently, 
mass spectrometry has proven critical in biomarker identification as well as glycoproteomic 
profiling. Research in the last 10 years on HCC biomarkers in blood is summarized in Table 3. 
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IV. Non-Mass Spectrometry Based Methods 
a. Immunoassays 
HCC biomarker studies that do not involve mass spectrometry have predominantly centered on 
the use of ELISA kits or other related immunoassays. In these ELISAs, sample preprocessing is 
minimal and relatively simple absorbance measurements can be performed. These tests are 
ideal in a clinical setting where they can be performed with a simple set-up by a technician. The 
use of a clinical ELISA does require the use of a well-validated antibody for that assay. If such 
an antibody is available then it is difficult to surpass the performance of an ELISA in terms of 
analytical sensitivity and specificity. Additionally, diagnostic sensitivity, specificity, and AUC 
values can be quickly derived from these simple tests. Of course the results from these assays 
depend on the sample sets being tested where for different sets there may be a mix of different 
etiologies, early versus late stage samples, a mix of genders and the presence of confounding 
diseases. Nevertheless, ELISA assays have been generally used for large scale validation of 
HCC markers for early detection. The markers being tested for HCC are generally glycoproteins 
but these ELISAs measure the level of protein and do not take advantage of the glycan 
structure as a potential marker for early detection. 
There have been several validation studies on the currently used markers for HCC 
including AFP, DCP and AFP-L3. Among these is a study conducted by Marrero and coworkers 
under the auspices of the National Cancer Institute (NCI) Early Detection Research Network 
(EDRN) (Marrero et al., 2009). In this study there were a total of 836 patients of which 417 were 
cirrhosis controls and 419 were HCC cases of which 208 had early stage HCC. The results of 
these studies are shown in Table 2 where AFP had the best AUC value at 0.8, followed by DCP 
at 0.72 and AFP-L3 at 0.66. The optimal AFP cutoff value was 10.9 ng/mL, leading to a 
sensitivity of 66%. When only the samples with very early HCC were evaluated the AUC value 
was 0.78. Thus, according to this study AFP was more sensitive than DCP and AFP-L3 for the 
diagnosis of early stage HCC. 
Another alternative marker for HCC is GP73 that has been analyzed as a biomarker with 
immunoassays. Although GP73 is a known glycoprotein with fucosylation suggested to play a 
discriminatory role in HCC diagnosis (Hu et al., 2010), recent studies have focused instead on 
relative abundance in serum protein level with primarily ELISA kits (Riener et al., 2009;Hu et al., 
2010;Mao et al., 2010;Morota et al., 2011;Zhang et al., 2016), with AUC values that range from 
0.89 via a western blot study (Hu et al., 2010) to 0.94 in a full epidemiologic study with over 
4000 participants (Mao et al., 2010). In another study, immunoassays were used to compare 
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GP73 with hemopexin, fucosylated hemopexin, PIVKA-II, and AFP (Morota et al., 2011). 
Interestingly, PIVKA-II was found to have the highest total discriminatory power (AUROC=0.90) 
among several types of chronic liver diseases of different etiologies; however, GP73 was found 
to have higher discriminatory power (AUC=0.90) for HCC and cirrhosis vs. hepatitis and normal 
samples (Morota et al., 2011). The most recent study found the sensitivity and specificity of 
GP73 to be 74.6% and 97.4%, respectively, with a cutoff of 8.5 relative units (Mao et al., 2010), 
which is higher than any reported specificities for haptoglobin, but lower in sensitivity (Shang et 
al., 2017). In other recent work, GP73 and AFP-L3 were studied for their capabilities for 
diagnosing AFP-negative HCC (Zhao et al., 2018). It was found that, by using these two 
markers together, one could improve the diagnostic accuracy and sensitivity for detection of 
AFP-negative HCC. Other immunoassays have suggested beta-catenin as a biomarker for HCC 
with sensitivity and specificity of 96.9% and 92.6%, respectively (Zekri et al., 2011). However, 
because these results have not been pursued further, their use is limited. Nevertheless, 
immunoassay techniques have been essential for current clinical assays for HCC early 
detection. 
b. CE-based assays for HCC markers 
Capillary electrophoresis (CE) has proven to be a valuable tool to separate glycans. This 
method is dependent on the differential migration of analytes in an applied electric field. It has 
been used to study the N-Glycan profile of the protein Hemopexin in patient serum in HCC 
versus cirrhosis to detect HCC (Debruyne et al., 2010). In this study, Hemopexin was purified 
from patient serum with heme agarose be ds; IgG was depleted with protein A agarose, and 
Hemopexin glycans were removed and labeled for detection. The glycans were analyzed with 
CE and detected based on a fluorescent probe. Branching alpha-1,3-fucosylated multi-
antennary glycans on Hemopexin were increased in the HCC group compared with cirrhosis, 
fibrosis, and healthy volunteers as compared to non-modified biantennary glycans, which 
decreased progressively across patients from fibrosis to cirrhosis to HCC. This Hemopexin 
glycan marker differentiated patients with HCC and cirrhosis from healthy volunteers and 
patients with cirrhosis or fibrosis with a sensitivity and specificity of 79% and 93%, respectively. 
c. Lectin Fluorophore-linked Immunoabsorbent Assays 
1. Method 
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Methods for antibody and lectin arrays for glycoprotein detection have been reviewed elsewhere 
(Patwa et al., 2010). The lectin-FLISA method has advantages as a simple method to detect the 
response of various lectins to target proteins in biofluids (see Figure 1). Often, the changes in 
glycan structures are more informative than the absolute changes in protein levels as 
determined by ELISAs. The lectin-FLISA uses an antibody that has had its glycans oxidized so 
they will not interfere with the analysis. The antibody selectively extracts the target protein from 
the serum, and a fluorescently labelled lectin is used to detect glycan structures with the 
appropriate structural moiety. The list of lectins and their corresponding recognized glycan 
structures has been summarized in the literature (Clark and Mao, 2012). Much of the published 
work has targeted fucosylated glycans (Wang et al., 2009;Liu et al., 2010) but other lectins that 
detect other structures could also be used. The method has the advantage that it can be used in 
an ELISA format or on a microarray-based format for high-throughput assays. A disadvantage 
of the method is that the assay is only as good as the antibody used, and there might be cross 
reactivity from other components in complex fluids such as serum. Also, the lectins can detect 
total amounts of the target carbohydrate, but cannot distinguish subtle differences in the number 
of sugars present, such as the case for mono-, di, or tri fucosylation, where individual minor 
structures might serve as the optimal biomarker but might be masked by the total sugar 
detection (Zhu et al., 2014).  
2. Lectin-FLISA targeting fucosylation  
Taniguchi and coworkers (Kinoshita et al., 1991) have developed an antibody-lectin enzyme 
immunoassay to detect fucosylated alpha-fetoprotein in liver cancer. The use of fucosylated 
AFP has served as an alternative marker to AFP to detect HCC versus cirrhosis. The assay 
developed was similar to that described above where AAL was used as the lectin to detect AFP 
captured by an antibody on a microtiter plate. Taniguchi and coworkers also developed a 
method for enrichment of AFP to be used with this platform. The methodology measured highly 
fucosylated AFP diluted to 5 to 80 ng/mL in human serum. 
Mehta and coworkers (Comunale et al., 2009;Comunale et al., 2013) have also developed 
a lectin-FLISA that targeted fucosylation for early detection of HCC. They point out that AFP and 
core-fucosylated AFP can be produced under other circumstances than HCC, including other 
liver diseases, and is not present in all patients with HCC. Also, it is difficult to discriminate AFP 
levels in early-stage HCC from cirrhosis. They therefore used a lectin-FLISA to explore the 
levels of fuc-kininogen and fuc-A1AT in patient serum individually and in combination with the 
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level of AFP and also GP73 to distinguish between a diagnosis of cirrhosis and HCC. They 
found that the levels of fuc-Kin and fuc-A1AT were significantly higher in patients with HCC 
compared to cirrhosis. The optimal performance was obtained with a combination of fuc-Kin, 
AFP, and GP73 to result in a sensitivity of 95% and a specificity of 70%, and an AUC of 0.94. 
Thus they concluded that the fucosylated proteins can act as markers to detect HCC by 
themselves or could improve detection in combination with other markers at the protein level. 
In other work, Lubman and coworkers (Liu et al., 2010) used a lectin antibody array version 
of the lectin-FLISA to test 26 potential markers discovered with a mass spectrometry-based 
technique to distinguish early HCC from cirrhosis. In this method the antibodies were printed on 
glass slides and incubated with AAL lectin to detect fucosylation differences. The AAL was 
tagged with a fluorescent probe, and each spot was quantitatively detected with a microarray 
scanner. C3, CE, HRG, CD14, and HGF were found to be potential biomarker candidates to 
distinguish early HCC from cirrhosis with a sensitivity of 72% and a specificity of 79%. 
It should be noted that a mass spectrometry version of the lectin-FLISA was recently 
developed by Yoo and coworkers (Ahn et al., 2012) to detect HCC. This method will be 
discussed below. 
d. 2-D Gels and Lectin Analysis 
Lectin analysis has also been used with 2-D gel electrophoresis to search for HCC markers. 
Block and coworkers (Block et al., 2005) performed glycoproteomic analysis with 2-D gels to 
identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Their 
strategy used several lectins to extract fucosylation from serum and then analyzed the bound 
and unbound fractions with 2-D gels. This analysis showed there were clearly proteins that were 
fucosylated that were upregulated in the bound versus the unbound fraction. An HPLC analysis 
of the glycans from the bound fraction showed the presence of fucosylated glycans as 
compared to the unbound fraction. They performed the experiment for the bound fractions for 
HCC versus non-HCC (healthy), and found that there were proteins that were upregulated in the 
HCC sample; with further analysis these proteins were found to be highly fucosylated. One such 
protein of interest was fucosylated GP73, which was also tested in human samples and was 
found to be upregulated significantly compared to other control groups. 
The summary of the four non-mass spectrometry methods is presented in Table 4. 
Table 4. Non-mass spectrometry Methods for Glycoprotein Marker Discovery 
Au
tho
r M
an
us
cri
pt
Immunoassays (ELISA) Very sensitive and specific, but measures protein level but not 
sensitive to glycan structure 
CE-based assays Specific for separation and profiling of glycans 
Lectin-FLISA Specific for target glycoproteins and can detect changes in glycan 
structures 
2-D gels/lectin analysis Can monitor global changes in the proteome for large number of 
proteins 
 
V. Discovery−Mass Spectrometry-Based Assays 
a. Mass Spectrometry versus non-Mass Spectrometry Methods 
In this section, we will review the advances in mass spectrometry for the analysis of glycans and 
glycopeptides related to early detection of HCC. There are several key advantages for mass 
spec based techniques (see Table 5). One of these advantages is that MS assays do not 
require antibodies, although antibodies are sometimes used to enhance MS based assays in 
the case of studies of target glycoproteins. The performance and availability of antibodies may 
vary and affect an assay whereas MS is a more general technique and can be performed on 
any protein. With no need of prior knowledge of the protein identity, MS can perform large scale 
screening of glyco-marker candidates in complex biological samples that underwent 
glycosylation changes, which can be efficiently conducted for in-depth quantitation of glyco-
markers with the support of sophisticated MS softwares. An additional advantage of MS assays 
such as MRM for example is that the assays can be multiplexed for many different proteins 
simultaneously. Also, the advent of tagging methods such as iTRAQ and TMT labels has 
allowed quantitative multiplexing of samples not readily possible by current non-MS methods. 
This feature is essential in biomarker studies comparing multiple samples. Probably the most 
significant advantage of MS based techniques is the ability to obtain detailed structural analysis 
of glycan structures as well as to pinpoint the glycosylation sites that underwent glycan changes 
in complex biological samples, which might have direct impact on biomarker studies. Although 
CE/lectins and gel/lectins provide some information on glycan structure, assays using these 
methods cannot provide the level of detail that modern MS-based techniques can achieve, 
especially in the in-depth structure information (structural isomers, linkage information, etc.). 
The main advantage of these tools compared to MS is that they do provide a means of visually 
monitoring changes in glycan composition. Also, these non-MS based techniques do not require 
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the sophisticated instrumentation or expense of modern mass spectrometers. Nevertheless, as 
discussed in the following sections, mass spectrometry can provide a level of detail in glycan 
analysis not available to any other method.  
Table 5. Advantages of mass spectrometry for glycan analysis and related assays 
1. No antibodies or lectins required 
2. Multiplex capabilities with quantitative analysis 
3. Ability to obtain detailed glycan structures for biomarker studies 
 
b. Methods to Enrich Glycoproteins and Their Glycans/Glycopeptides 
Due to low abundance of glycoproteins and the inherent structural complexity of protein 
glycosylation, isolation/purification of glycoproteins and their glycoforms such as glycans and 
glycopeptides is an essential element of successful characterization of the glycoproteome, 
glycome and glycopeptidome. Advanced analytical technologies have been developed to 
selectively enrich glycoproteins and their glycans/glycopeptides (Table 6), including lectin-
based affinity chromatography, hydrazide chemistry, hydrophilic interaction chromatography 
(HILIC), porous graphitized carbon (PGC) chromatography, and cotton wool SPE tips. Among 
these separation methods, lectin affinity chromatography and hydrazide chemistry can be 
performed either to capture glycoproteins at the protein level (Xu et al., 2007;Zhang, 2007;Wang 
et al., 2008;Liu et al., 2013) or capture glycopeptides at the peptide level (Chen et al., 2013;Yin 
et al., 2015;Tanabe et al., 2016). Whereas lectins have well-characterized sugar specificities to 
capture specific carbohydrate residues in glycoproteins/glycopeptides, hydrazide chemistry can 
be used in the unbiased enrichment of glycoproteins/glycopeptides. PGC columns or tips are 
the most commonly used strategy to enrich glycans from protein mixtures (Zhu et al., 2014). 
HILIC is a well-recognized technique that can effectively enrich glycans/glycopeptides (Yang et 
al., 2017), whereas cotton SPE tips have been recently developed to purify glycopeptides and 
glycans (Selman et al., 2011). These strategies of glycoprotein/glycan/glycopeptide enrichment 
can be further coupled with advanced mass spectrometry analysis (An et al., 2009;Kailemia et 
al., 2014) with LC-MS/MS, QIT-TOF, MALDI-TOF/TOF, and MRM to discover more clinically 
relevant markers with greater sensitivity and specificity (Dai et al., 2009). Table 6 summarizes 
the methods for the enrichment of glycans/glycopeptides/glycoproteins. 
Table 6. Methods for Enrichment of Glycans/Glycopeptides/Glycoproteins 
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Method Advantages 
Lectins Selective method for enrichment of specific glycan structures on 
glycoproteins and glycopeptides 
Hydrazide A general unbiased method for glycopeptide enrichment but with loss 
of some glycan information 
Graphitized carbon 
Chromatography (PGC)  
PGC tips can be used to enrich glycans from small amount of 
sample 
HILIC chromatography A general method that can effectively enrich glycans/glycopeptides 
based on hydrophilicity 
MW cutoff filter Can effectively separate large glycans/glycopeptides from smaller 
peptides 
Size Exclusion 
Chromatography 
Rapid method to enhance detection of N-linked glycosylation sites 
 
c. MALDI-MS Profiling of Glycans 
1. Method 
MALDI-MS has been used as a convenient method to profile glycans. The MALDI processed 
applications have been reviewed in prior publications (Michael et al., 1992;Zhao et al., 
2006;Fukuyama et al., 2008). Because there is no intrinsic pre-separation in the MALDI 
process, the method is best for simple mixtures. In most glycan biomarker studies, the glycans 
from a single isolated protein r a limited number of proteins is usually studied. Also, generally 
the glycans must be derivatized, usually with permethylation, to enhance the volatility and to 
improve the limit of detection. It is also possible to perform an LC-MALDI experiment (Young 
and Li, 2006;Chen et al., 2017b) for more-complex mixtures, where the glycans can be 
separated and placed on different spots on the MALDI plate to provide a simpler spectrum for 
interpretation. It should be noted that a major advantage of this method is that rapid screening 
of a large number of samples can be accomplished with a high-capacity MALDI plate and 
modern high repetition rate lasers. 
2. Targeted MALDI Profiling for Haptoglobin (Hp) and Alpha-1-Acid Glycoprotein (AGP) 
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With a quantitative MALDI-QIT-MS/MS approach with only 10 µL of serum in individual patients, 
Lin and coworkers identified that fucosylated N-glycans in Hp were significantly elevated in 
pancreatic cancer compared to chronic pancreatitis (Lin et al., 2011). In this study, Hp was 
isolated with a monoclonal antibody, and the glycans removed for analysis with MALDI-MS 
where the glycans were also permethylated. Eight desialylated N-glycan structures of 
haptoglobin were identified, where a bifucosylated triantennary structure was reported for the 
first time in pancreatic cancer samples. Core and antennary fucosylation were both elevated in 
pancreatic cancer samples compared to samples from benign conditions. Structural analysis 
could be provided with the QIT-MS/MS capabilities (Nishikaze, 2017). Fucosylation degree 
indices were calculated, and showed a significant difference between pancreatic cancer patients 
of all stages and the benign conditions. This study showed the feasibility of MALDI-MS as an 
assay for cancer from serum samples. 
The MALDI-MS profiling method was applied by the same group to study the glycans 
expressed in the different HCC etiologies (see Figure 2) (Zhu et al., 2014). A unique pattern of 
bifucosylated tetra-antennary glycan, with core and antennary fucosylation, was identified in 
HCC patients. Quantitative analysis indicated that the increased fucosylation degree was highly 
associated with HBV and ALD-related HCC patients compared to that of the corresponding 
cirrhosis patients. Notably, the bifucosylation degree was distinctly increased in HCC patients 
versus that in cirrhosis of all etiologies. The elevated bifucosylation degree of haptoglobin could 
discriminate early-stage HCC patients from cirrhosis in each etiologic category. This unique 
pattern of bifucosylated tetra-antennary N-glycan could outperform the clinically used AFP to 
discriminate early-stage HCC from cirrhosis (AUC=0.834, p<0.0001) (Zhu et al., 2014). More 
recently, Zhu et al. have developed an antibody-extraction column, which improves markedly 
over immunoprecipitation to isolate Hp for this experiment. This antibody column can extract Hp 
from 20 µL of serum in 40 min with >90% recovery (Zhu et al., 2015). 
In other work by Zhang et al. (Zhang et al., 2011), N-linked changes in serum Hp beta chain 
were studied with MALDI-QIT-MS. The Hp was isolated from serum using a Hp-antibody column 
and the glycans removed for analysis. In this work they specifically studied patients with HBV 
etiology which is predominant in China. Their studies included 20 each of HBV patients, 
cirrhosis patients, and HCC patients and also normal controls. They found that two fucosylated 
glycans, whose structures were identified with MS/MS in the QIT, were clearly elevated in the 
cirrhosis and HCC patients relative to HBV and normal. This result was also confirmed with 
lectin blot using AAL lectin. 
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In related work, Liang et al. applied MALDI-MS glycan profiling to AGP from serum where 
AGP was isolated with a chemical precipitation method (Liang et al.). The AGP glycan profile 
was more complex than Hp, and yielded nine peaks in the MALDI MS spectrum. It was shown 
that a trifucosylated tetra-antennary glycan could distinguish HCC from cirrhosis samples with a 
performance for NASH-based samples that was comparable to AFP. Wang et al. studied 
glycans from IgGs isolated from serum and analyzed them with MALDI-MS (Wang et al.). They 
found that several glycans from the IgGs improved detection of HCC versus cirrhosis relative to 
AFP. The ratio of galactose was particularly promising. 
3. Global MALDI Screening to Profile HCC Markers in Serum 
Goldman and coworkers (Goldman et al., 2009) evaluated the use of total glycan profiling with 
MALDI-MS to identify markers for HCC. In several studies they used 10uL of serum; they 
removed the N-glycans with PNGaseF and solid-phase extraction, and permethylation was used 
to process the glycans for MALDI TOF-TOF MS. They studied HCC samples and controls with 
chronic liver disease and without liver disease. They used novel computational methods to 
analyze the complex set of glycan patterns obtained, and they found three selected N-glycans 
that could classify HCC with 90% sensitivity and 89% specificity in an independent set of 
patients with chronic liver disease. Because these samples were obtained from a hospital in 
Egypt, the marker performance might prove different for other populations. Although these 
glycans could identify HCC from cirrhosis and fibrosis, the proteins associated with the glycans 
are not known and are probably from high-abundance proteins. The latter makes it difficult to 
develop an antibody based version or ELISA to detect these markers. 
4. MALDI-Imaging of Tissues in HCC 
Although this review is focused on analysis from serum, it should be noted that there has been 
significant recent activity in the area of MALDI imaging which can evaluate changes in tissues 
during the progression of cancer. Recent work in this area related to HCC is that of Powers and 
coworkers, where they used MALDI-imaging to study changes in glycan structure between 
normal and HCC tissue samples (Powers et al., 2015). The method can be used in fresh tissues 
or in FFPE, where PNGaseF is sprayed on the sample to release N-glycans directly on the 
tissues mounted on glass slides before adding the MALDI matrix. They evaluated FFPE 
samples of HCC tissues using this method and detected over 30 N-glycans. Distinct differences 
were observed between the HCC versus normal samples. They also were able to study the 
distribution of singly fucosylated N-glycans detected in these tissues and could compare them to 
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the staining pattern obtained using a core fucose binding lectin. In more recent work by this 
group, they analyzed 138 HCC tissues and compared the N-linked glycans in cancer tissue to 
tissue with liver cirrhosis (West et al., 2018). Ten glycans were found to be significantly elevated 
in HCC tissues compared to cirrhosis. These glycans were found to be with increased levels of 
fucosylation and/or with increased levels of branching. They also found that increased levels of 
fucosylated glycoforms were associated with a reduction in survival time (West et al., 2018). 
d. ESI-MS Profiling of Glycans 
1. Method 
Electrospray ionization has been used to profile glycans from various biofluids in an attempt to 
find markers for HCC and other cancers. A major advantage of ESI is that it can readily be 
coupled to HPLC to pre-separate complex glycan mixtures. The method allows total glycan 
analysis from serum or other biofluids or of glycans from target proteins. The glycans can be 
analyzed without prior derivatization or with derivatization to increase detection sensitivity. The 
ESI source can be coupled to any type of mass spectrometer, and has been used with Orbitraps 
for structural analysis of the glycans using CID and HCD for MS/MS analysis. It can also be 
interfaced to ion mobility or PGC columns to separate glycan isoforms. The glycan profile often 
provides a distinct signature of a cancer versus control; however, the glycans cannot be 
associated with a specific protein so that an antibody-based assay cannot be readily developed. 
2. Global Profiling of Glycans with LC-ESI-MS for Biomarkers of HCC 
LC-ESI analysis has been used to profile glycans for a number of cancers, including ovarian 
(Leiserowitz et al., 2008;Kim et al., 2014), pancreatic (Zhao et al., 2007), HCC (Chandler et al., 
2013;Tsai et al., 2014;Wang et al., 2017), and prostate cancer (Hua et al., 2011), among others. 
There have been a number of studies on global screening of glycans from serum for HCC 
biomarker studies. Ressom and coworkers (Tsai et al., 2014) used LC-ESI-MS to analyze N-
glycans in sera from 183 patients to distinguish HCC from cirrhotic controls. N-glycans were 
released from serum proteins with PNGaseF and the glycans were permethylated with a solid-
phase permethylation procedure. The glycans were profiled with LC-ESI interfaced to an 
Orbitrap Velos MS. Several glycans that were found to be significantly up- or down-regulated in 
their cohorts were identified for further analysis. These glycans were then analyzed with 
targeted MRM analysis, and 11 N-glycans were identified as being statistically significant 
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between HCC cases and cirrhotic controls. This study demonstrated the use of an integrated 
approach for profiling and targeted assays for biomarker analysis of glycans. 
3. Profiling of Glycans for Specific Proteins with LC-ESI-MS for Biomarkers of HCC 
The alternative strategy to global profiling of glycans is to isolate a targeted protein from serum 
for analysis of its glycan content. This strategy has been performed for HCC for a number of 
different target proteins. One important target has been Haptoglobin, as shown in prior work on 
the MALDI-MS analysis of its glycan content. In the work of Lubman and coworkers (Zhang et 
al., 2015b), a workflow was developed that isolated Hp with an HPLC-based affinity column 
followed by glycan removal, extraction and desialylation. The fucosylated glycans from Hp were 
derivatized with Meladrazine which is a reagent developed in China (Tie and Zhang, 2012) that 
can significantly enhance the sensitivity for ESI-MS detection . The separation of the glycans 
with a HILIC column resulted in detection and quantitation of eight glycans with less than 1 µL of 
serum. The ratio of the various fucosylated peaks to their corresponding non-fucosylated forms 
showed that the fucosylated glycans are upregulated in the case of early HCC samples versus 
cirrhosis. In particular, a relatively low abundance bifucosylated tetra-antennary form might 
serve as a marker of HCC as shown in their prior MALDI-MS work. 
A different strategy developed by Mechref and coworkers (Huang et al., 2017) involved the 
use of isomeric profiling to identify glycan markers for cancer. Isomeric forms of glycans were 
separated and identified based upon separations with elevated temperatures in a PGC column 
followed by ESI-MS in an Orbitrap Velos MS (see Figure 3). This method separated isoforms of 
sialic acid, including the isoforms of sialic acid with alpha-2,3 and alpha-2,6 linkages. A 
comparison of non-isomeric and isomeric permethylated glycan forms from Hp released from 
patient serum was achieved with C18 and porous graphitic carbon (PGC) columns. This method 
was used to distinguish early-stage HCC from cirrhosis, whereby 8 out of 34 glycans identified 
by PGC-LC-MS/MS were found to be significant due to the isomeric distributions of a particular 
glycan. This work represents the first example of the use of isoforms of glycans as potential 
cancer biomarkers. Other attempts have been made to distinguish glycan isoforms from serum 
with ion mobility spectrometry, although at this point with limited success (Gaye et al., 2012). 
An alternative strategy developed by Clemmer and co-workers (Isailovic et al., 2012) used 
ion mobility spectrometry-mass spectrometry (IMS-MS) to profile serum N-linked glycans for 
HCC (see Figure 4). In the ion mobility strategy, ions separate according to their mobility in a 
drift gas under the influence of an electric field. The drift time depends on the collisional cross 
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section of the ion, which depends on its shape. The result is that isomers can often be 
separated that could not be detected in mass spectrometry alone. In this work, they profiled the 
glycans from HCC, cirrhosis, and normal with the IMS-MS technique, and they found that the 
ion mobility profiles for as many as ten different mass-to-charge ratios for glycans together with 
supervised PCA analysis distinguished the different disease states. The resolution of ion 
mobility is limited, but they nevertheless speculate that they were able to distinguish some 
isomer forms based on differences in the ion mobility. The method has distinct advantages in 
terms of speed of analysis compared to other separation methods. In other work, Li and 
coworkers developed a relative quantification platform for quantitative analysis of N-glycans 
released from human serum protein digests by combining aminoxy TMT labeling with CE-ESI-
MS/MS, which has been demonstrated to be efficient in resolving glycan isomers and improving 
the relative quantification accuracy (Zhong et al., 2015). A review that details advances in the 
use of IMS to separate isomeric glycans has recently been published (Chen et al., 2017a).  
e. ESI-MS of Glycoproteins/Glycopeptides to Profile Proteins Related to HCC 
1. Method 
The description for ESI-MS of glycoproteins and glycopeptides is similar to that described 
above; however, there are several experimental issues that must be considered. In the case of 
glycopeptides, there can be other interfering peptides that must be removed or separated from 
the non-glycosylated peptides. The peptides tend to have a much higher ionization efficiency 
than the glycopeptides, and will suppress the signal from the glycopeptides. Also, an advantage 
to study glycopeptides is that one can identify site specificity for the glycans, which might be an 
important marker in itself for disease. An issue to study glycopeptides with MS/MS is that 
various methods are required for analysis of the peptide backbone and glycan structure. Some 
of these methods that have been used in HCC biomarker studies will be discussed in this 
section. Alternatively, one can study the glycoproteins based on the selective isolation of the 
glycoproteins with certain structures with lectin methods, and study of the peptide changes. 
There is some loss of structural information in this strategy, but it can differentiate protein levels 
according to the expression of specific glycan structures. 
2. Lectin Extraction of Proteins 
In one strategy used by several groups (Yang et al., 2006) for biomarker analysis in serum, 
lectin columns were used to quantitatively extract glycoproteins. This method has been used in 
Au
tho
r M
an
us
cri
pt
studies of HCC versus cirrhosis in the work of Lubman and coworkers (Liu et al., 2010) to study 
differential changes in fucosylation. In this work, a lectin array was first used to establish that 
AAL and LCA provided the largest changes in response between HCC and cirrhosis in serum. 
The proteins in the sera samples were labeled with Exactag labels for quantitative analysis and 
passed through a lectin AAL or LCA column for further analysis. The extracted glycoproteins 
were digested with trypsin and analyzed with nanoLC-MS. The changes in the fucosylation level 
were monitored through the tagged peptides. They found five proteins, including complement 
C3, ceruloplasmin, histidine-rich glycoprotein, CD14 and hepatocyte growth factor, that were 
potential markers to detect early-stage HCC versus cirrhosis. The combination of the five 
proteins had an AUC of 0.81. This work showed that there was a significant increase in the level 
of fucosylation in serum proteins in early HCC versus cirrhosis as a potential means for early 
detection. 
3. Lectin Extraction of Glycopeptides 
3a. Integrated analysis of lectin-extracted glycopeptides 
In a related but alternate strategy to that discussed in the above section, Narimatsu and 
coworkers (Kaji et al., 2013) developed an integrated strategy with lectins to extract 
glycopeptides from serum to analyze biomarker candidates for HCV/HBV Infection-associated 
liver fibrosis and HCC. The strategy focused on candidate glycoproteins that are expressed in 
the original tissues of the cancer and that carry glycan structures associated with 
carcinogenesis, in this case HCC. They analyzed the glycan profiles of culture media of HCC 
cell lines with lectin arrays, and found that AAL and DSA signals were significant. They used 
lectin affinity chromatography with different combinations of these lectins to extract 
glycopeptides from digested proteins from the culture media and patient serum, and analyzed 
the glycopeptide profile with IGOT (isotope-coded glycosylation-site-specific tagging), where 
they remove the glycan and label the site with 18O and analyzed with nano-LC-MS on a QTOF 
MS. The glycoproteome profile was compared, where they found 744 first-step candidates from 
AAL extraction. They selected 21 of these candidates in patient serum based on liver 
expression and the availability of an effective antibody. A verification of the glycan alteration 
was conducted using pooled sera with lectin arrays to verify enhancement of fucosylation 
associated with HCC and detection of HCC-associated enhancement of fucosylation on the 
candidate glycoproteins with AAL-fractionation followed by Western blotting. However, they did 
not look for markers of early HCC in this study but rather were more focused on fibrosis.  
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In other work by Tanabe and coworkers (Tanabe et al., 2016), a novel strategy was used to 
perform global screening of glycopeptides in serum to discover HCC markers. The proteins in 
patient serum were digested with trypsin, and enriched first with ultrafiltration to eliminate 
peptides and small glycopeptides, and further enriched with AAL lectin-based affinity 
chromatography. The glycopeptides were analyzed with LC-ESI-QTOF MS, where custom 
software was used to screen thousands of AAL-enriched glycopeptide peaks over large 
numbers of samples. Glycopeptide candidates were further isolated and identified with LC-
MS/MS after removal of glycans with PNGaseF. The glycan structure was proposed based on 
MS/MS analysis. They identified a glycopeptide from AGP with multi-fucosylated tetraantennary 
N-glycans that was significantly elevated in HCC patients. The ROC curves for HCC versus 
cirrhosis provided values of an AUC=0.86 for HCC HCV versus cirrhosis and an AUC=0.93 for 
HCC HBV versus cirrhosis. However, because the stage of the patients was not provided, it was 
not clear if these were mainly early or late stage HCC patients. 
3b. Lectin Extraction with Truncation of Glycan Structure 
One of the issues to study glycopeptides has been to unravel the often complex structures of N-
linked glycans. One method that has been used to study the structure of glycans involves initial 
removal of selected carbohydrate units with enzymes followed by analysis of the remaining 
glycan with CE(Varadi et al., 2013) or LC (Wu et al., 2010) or mass spectrometry. In one study 
by Yin and others, a method for mass-selected site specific core-fucosylation of serum proteins 
in HCC was developed (see Figure 5) (Yin et al., 2015). This method involved initial depletion of 
high-abundance proteins, trypsin digestion of the remaining proteins, iTRAQ labeling of the 
peptides, LCA enrichment of core-fucosylated peptides, followed by endoglycosidase F3 
digestion before mass spectrometry analysis. The endoglycosidase digestion removed most of 
the glycan structure and left the core-fucosylation structure intact for mass spectrometry 
analysis. This strategy simplified the detection of these core-fucosylated structures and 
increased detection sensitivity compared to the intact glycan. In this study, they detected 1,300 
CF peptides from 613 CF proteins from patient sera, where 20 CF peptides were differentially 
expressed in ALD-related (alcohol) HCC samples compared with ALD-related cirrhosis samples 
and 26 CF peptides changed in hepatitis C virus (HCV)-related HCC samples compared with 
HCV-related cirrhosis samples. Among these there were three CF peptides from fibronectin 
upregulated in ALD-related HCC samples compared to cirrhosis with an AUC value of 0.89 at 
site 1007 for detection of early HCC. When combined with the AFP value, the AUC reached to 
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0.92; therefore, CF peptides of fibronectin might serve as potential biomarkers for early-stage 
HCC screening in ALD-related cirrhosis patients. 
f. Analysis of Target Glycoproteins from Patient Serum with an Intact Glycopeptide 
Approach 
1. Method  
The ability to analyze intact glycopeptide analysis with mass spectrometry offers great 
advantages for biomarker discovery based on the ability to define glycan sites and structures. 
However, the analysis of intact glycopeptides has remained difficult due to the complexity of the 
glycopeptide structure, which contains a carbohydrate and a peptide structure, the low 
ionization efficiency and low abundance of glycopeptides compared to peptides in protein 
digests, and difficulties in data interpretation. The glycopeptides can be enriched from the 
peptides by a number of methods, including lectin or HILIC. However, the ability to analyze the 
glycopeptides has remained a challenge. In recent work, there have been a number of 
techniques developed to deal with this problem (Table 7), including collision-induced 
dissociation (CID)/electron-transfer dissociation (ETD) (Alley et al., 2009), CID/higher-energy 
collisional dissociation (HCD) (Segu and Mechref, 2010;Lee et al., 2016), stepped HCD (Liu et 
al., 2017a;Yin et al., 2018), and electron-transfer/higher-energy collision dissociation (EThcD) 
(Yu et al., 2017;Chen et al., 2018;Glover et al., 2018), for example. The use of CID/ETD MS to 
analyze glycopeptides has been recently reviewed by Mechref (Mechref, 2012). CID can 
provide information related to the composition of the glycan unit attached to the peptide, 
whereas ETD can sequence the peptide because it causes only peptide backbone 
fragmentation and keeps the glycans intact. Stepped Collision Energy (SCE) HCD-MS/MS uses 
different collision energies in HCD-MS/MS to produce complementary fragments of the glycan 
and peptide. It has been found that SCE-HCD-MS/MS under 20-30-40% energies generated 
highly informative fragment ions for peptide and glycan of a glycopeptide for structural analysis 
(see Figure 6A) (Liu et al., 2017a;Yin et al., 2018). In other work by Heck and co-workers, ETD 
and HCD were combined to develop a hybrid technique called EThcD (Frese et al., 2012). In 
this method, a supplemental energy is applied to all ions formed by ETD to generate spectra 
with enhanced capabilities in glycopeptide studies (see Figure 6B). There has been extensive 
work on some of these techniques towards analysis of glycoproteins/glycopeptides for standard 
proteins, but more limited work for clinical samples as in serum. 
Table 7. MS/MS Methods for MS analysis of Intact Glycopeptides 
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CID/ETD CID provides information related to glycan structure/ETD provides sequence 
information of peptides  
CID/HCD Both CID and HCD result in glycan fragmentation/HCD also provides peptide 
backbone b-y ion fragmentation  
HCD/ETD HCD provides diagnostic glyco-oxonium ions which can be used to trigger the 
succeeding ETD dissociation and additional b and y ions of peptide backbones 
Stepped HCD Can generate highly informative fragmentations for peptide and glycan of a 
glycopeptide 
EThcD Combines ETD and HCD where a supplemental energy is applied to ions 
formed by ETD to generate both peptide and glycan structural information 
 
2. EThcD Analysis of Glycopeptides 
A recent strategy to analyze intact glycopeptides with mass spectrometry developed a 
quantitative EThcD-MS/MS method to determine changes in intact N-glycopeptides between 
early HCC and liver cirrhosis for Hp in patient serum (Zhu et al., 2018). In this work, Hp was 
immunopurified from 20 µL of serum followed by digestion with trypsin and GluC, glycopeptide 
enrichment with HILIC TopTips, and LC-EThcD-MS/MS analysis on an Orbitrap Fusion Lumos 
Tribrid mass spectrometer. The development of the Orbitrap mass spectrometer is an important 
advance for glycopeptide analysis. The EThcD method was developed by Li and coworkers (Yu 
et al., 2017), where HCD and ETD fragments could both be collected in a single spectrum to 
markedly improve intact glycopeptide characterization. Site-specific identification and 
quantitation of N-glycopeptides were achieved with novel software developed by Protein Metrics 
Inc.; i.e. Byonic and Byologic softwares (Bern et al., 2012). Byonic provides a means to interpret 
the structure of the glycopeptides, whereas Byologic provides a means to quantitate the 
structures. This software is also an important advance because manual analysis would be 
difficult and time-consuming. The analysis of patient serum resulted in 279 N-glycopeptide 
spectral matches that corresponded to 98 site-specific N-glycopeptides (Zhu et al., 2018). In 
addition, several key structures were found to be quantitatively different between early stage 
HCC and cirrhosis, including a bifucosylated tetra-antennary form reported in earlier work (Zhu 
et al., 2014). The combination of LC-EThcD-MS/MS and Byonic/Byologic software represent a 
potential major breakthrough for the analysis of intact N-glycopeptides. 
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The group of An (Lee et al., 2018) has also identified and quantified the site-specific 
glycopeptides of serum haptoglobin between gastric cancer and healthy controls with Q-TOF 
LC-MS/MS. Ninety-six glycopeptides of serum Hp were characterized across all cancer and 
control samples, where 3 glycopeptides exhibited exceptionally high fold-changes in gastric 
cancer (Lee et al., 2018). 
VI. Verification LC-MRM Analysis of Glycosylation 
1. Method 
LC-MRM serves as an alternative method for targeted protein quantification. The method has 
been used in complex mixtures, including patient serum where the proteins are digested into 
peptides, which are monitored with mass spectrometry. The peptides monitored for each target 
protein are selected according to criteria to optimize sensitivity and at the same time provide a 
peptide that is unique to that protein. In order to quantitate the peptide, an isotopically labeled 
reference peptide with the same sequence is used. The target peptides are selected in the 
mass spectrometer and fragmented; where several transitions are monitored. The method has 
great advantages in that one can multiplex large numbers of target peptides in modern mass 
spectrometers, it does not require an antibody, the assay once developed can be automated, 
and the data are highly reproducible compared to standard ELISAs. In the case of 
glycoproteins, the assay becomes more difficult because glycopeptide standards are generally 
not available. There have been several strategies developed for LC-MRMs of glycoproteins 
(Ahn et al., 2009;Song et al., 2012;Ruhaak and Lebrilla, 2015). Herein, we will just present 
some of those studies that directly pertain to detection of HCC. 
2. LC-MRM of IgGs in plasma 
In recent work, Goldman and coworkers (Yuan et al., 2015) developed a method for quantitative 
analysis of immunoglobulin subclasses and subclass specific glycosylation with LC-MS-MRM in 
liver disease. Immunoglobulins were first isolated from human plasma with protein A and G 
columns. The IgGs were digested with trypsin and subjected to LC-MS/MS. Goldman and 
coworkers developed a novel method whereby glycan oxonium ions and peptide-GlcNAc 
fragment ions were used to quantify glycoforms of IgG purified with affinity chromatography with 
normalization to a unique peptide associated with each IgG subclass. They found that HCC 
patients have increased circulating IgG1, IgG3, IgA1, and IgM compared to healthy controls. A 
comparison of HCC and Cirrhosis patients showed that HCC patients have a significantly higher 
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concentration of IgG1 and IgM but lower IgG2 concentration. An increase in galactose-deficient 
core fucosylated glycoforms was observed in cirrhosis and HCC patients. They also found that 
specific glycoforms such as FA2G0 and FA2B0 increase in all IgG subclasses, whereas the 
FA2G2 form decreases. This work in effect developed a method whereby quantities and 
glycoforms of immunoglobulins both change significantly in liver disease progression to HCC. 
Goldman and coworkers (Sanda et al., 2013) also developed a quantitative LC-MS-MRM 
method for site-specific glycoforms of Hp in liver disease. In this work, they first isolated Hp from 
plasma samples, where the Hp was added to an internal standard and digested with trypsin. 
The digest was treated with alpha-neuraminidase to remove the sialic acids to enhance the 
sensitivity for detection. A further digestion of the glycan with beta (1-4)-galactosidase further 
simplified the glycan structure. The glycopeptides were subjected to LC-MS-MRM, where the 
oxonium ions and peptide-GlcNAc fragments were monitored as MRM transitions. The T3 
glycopeptide of Hp was chosen for particular attention because of the large number of potential 
diagnostic isoforms. The combination of LC-MS-MRM with exoglycosidase digestion resolved 
isobaric glycoforms of the Hp T3 glycopeptide for quanitifcation of multiply fucosylated 
glycoforms. They found that 14 multiply fucosylated glycoforms increased significantly in the 
liver disease group compared to healthy controls. They also found that the tri- and tetra-
antennary singly fucosylated glycoforms are associated with MELD score and low platelet 
counts. The group recently carried out LC-MS-MRM quantification of core fucosylated N-
glycopeptides of serum proteins and found increased core fucosylation of five glycopeptides at 
the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of 
plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of 
additional six glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, 
N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican) 
(Ma et al., 2018). 
3. LC-PRM of AFP in Serum 
Most recently, An and coworkers (Kim et al., 2018) developed a quantitative LC-MS/MS-PRM to 
monitor fucosylated glycopeptides in serum AFP to distinguish between HCC and cirrhosis 
patients. Because AFP is normally present at low levels in serum, even in patients with liver 
disease, a more sensitive approach is required. To overcome the sensitivity issues, AFP was 
immunoprecipitated from serum, followed by trypsin digestion, neuraminidase treatment to 
remove sialic acids, and LC-MS/MS-based PRM analysis. With a combination of these 
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approaches, the MS detection limit was significantly improved (LOD < 2 ng/mL). The result 
showed that the relative percentage of fucosylated AFP (AFP-fuc%) had a better performance 
than serum AFP levels to differentiate early-HCC and cirrhosis (AUC=0.962) with a sensitivity of 
92.3% (Kim et al., 2018).  
4. Lectin-FLISA based MRM 
A mass spectrometry version of the lectin-FLISA was recently developed by Yoo and coworkers 
(Ahn et al., 2012;Ahn et al., 2013) to detect HCC. In this work (Ahn et al., 2012), fucosylated 
proteins from plasma were captured onto AAL lectin immobilized on beads (see Figure 7). The 
proteins were digested with trypsin and the samples were spiked with stable isotope-coded 
internal standards of the target peptides to be quantified with MRM mass spectrometry in a 
triple-quadrupole mass spectrometer. They studied HCC of HBV etiology and used controls 
from cirrhosis, HBV patients, and healthy people. They found that AGP, AACT, A1AT, and 
Ceruloplasmin were potential markers. The AUC from these markers ranged from 0.73 to 0.92, 
and combinations of these candidates yielded an AUC of >0.95. The mass spectrometry version 
of the lectin-FLISA has distinct advantages in that it eliminates the use of antibodies and 
associated problems such as cross reactivity. The MRM can allow marker multiplexing where 
large numbers of peptides can be analyzed simultaneously. The assay can also be performed 
on a very standard triple quadrupole mass spectrometer. Also, MRM assays can be automated 
to analyze large numbers of samples and tend to be more stable than conventional ELISAs. 
5. Other Lectin-Based MRM Assays for HCC 
In work by Qian and coworkers (Zhao et al., 2011), a method for site-specific quantification of 
core fucosylated glycoproteins with MRM-MS was developed. In this assay, a serum sample 
with bovine thyroglobulin added was first enriched at the protein level with LCH lectin. The CF 
proteins underwent trypsin digestion, and a normalized internal standard, which is a pool of CF 
peptides from normals with CF peptides from bovine thyroglobulin, were labeled with 18O was 
added to the sample and was further purified using ultrafiltration. The CF peptides underwent 
partial deglycosylation with Endo F3 to remove most of the glycan structure to thus increase 
ionization efficiency. The CF peptides underwent MRM-MS with a triple quadrupole MS; in the 
MS2 spectrum, product ions PGn+, yG+, and y+ appeared regularly and with high abundance. 
These ions were used for MRM quantification, and were applied to HCC and normal serum 
samples with the peptide markers; see Communale et al (Comunale et al., 2006). Their studies 
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did not show a significant difference between the healthy controls and HCC groups for the CF 
levels of seven peptides; however, these were preliminary results. 
In more recent work by Lubman and coworkers, a similar assay was designed to validate 
markers of core-fucosylated proteins from previous work (Yin et al., 2015). In this method, 
serum samples from HCC, cirrhosis, and a pool of normal standards was first depleted of 
albumin and the IgGs with a spin column. At this point, standard proteins, which were targets of 
analysis, were added to the serum to enhance the ability to detect the peptides with MS/MS. 
The remaining proteins were digested with trypsin, and the CF-glycopeptides were extracted 
with LCA lectin. These CF-peptides were labeled with iTRAQ tags, and the samples were 
combined. The CF peptides were treated with endoF3 to remove most of the glycan structure 
and leave the truncated CF stem. The CF peptides were subjected to MRM analysis on an 
Orbitrap Q-Exactive. This method yielded a relative type of MRM where one can compare the 
changes in HCC CF-peptides to that of cirrhosis, and can use the pool of normal controls to 
standardize the signals. This work is currently underway to validate CF-fibronectin as a marker 
of early stage ALD-based HCC. 
 
VII. Conclusion: 
There has been great progress in the development of methods to analyze glycoproteins from 
patient samples, including plasma and serum. These methods will be essential to discover and 
validate markers for detection of early-stage HCC where treatment can be effective. They might 
also be used for diagnosis, prognosis, and therapeutic treatment, where often the glycan 
structures might change during the course of cancer progression. These methods have included 
mass spectrometry methods to analyze glycans that have been removed from the protein or 
intact glycopeptides, which retain the glycan structure and site specificity. These methods can 
be applied to the global glycoprotein content of serum, or more often they can be applied to 
target proteins such as Haptoglobin, Hemopexin, or Kininogen, for example, which have been 
proven to have diagnostic utility in cancer.  
Glycans have been analyzed with methods such as MALDI generally for target proteins and 
also with electrospray, where the glycans have been analyzed for either target proteins or large 
numbers of glycoproteins from serum. Other methods such as ion mobility have also been 
employed to separate isomeric structures. Glycan analysis has often proven diagnostic of HCC 
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versus cirrhosis, but the diagnostic glycans might not be unique to HCC and are often found in 
other cancers. An antibody-based method to screen a large number of samples cannot be 
readily developed. Alternatively, there have been significant developments to analyze 
glycopeptides, where various methods, including stepped HCD and EThcD, have been 
developed to obtain the sequence of the peptide backbone and the glycans. In addition, the 
development of new software that can analyze the many glycopeptide isoforms and also 
quantitate these isoforms have made possible the identification of specific isoforms that might 
be potential markers of HCC. The use of PGC columns has recently shown the ability to 
separate these isoforms for analysis.  
Although a number of potential biomarker candidates has been identified, validation of 
these markers in large Phase-3 biomarker validation sample sets such as the Hepatocellular 
Carcinoma Early Detection Strategy study (HEDS) set sponsored by the EDRN will be 
necessary before these markers can be further considered for clinical use. There have been 
various mass spectrometry-based techniques developed for such validations of glycopeptides 
such as a glyco-MRM and a lectin-FLISA based MRM. With the development of new 
technologies, we expect even more advances towards analysis of glycoproteins from patient 
samples. Nevertheless, the future of this field appears very exciting with many possibilities for 
clinical applications.  
The success of future work will depend on the new instrumental developments described 
herein, but will also depend heavily on the quality, type, and number of clinical samples 
available. These issues will present important challenges in this work. The quality of the 
samples is essential and the NCI-EDRN has developed standard operating procedures (SOPs) 
for collection, processing, and storage of samples to eliminate these issues from affecting the 
biomarker discovery and verification process. Also the types of samples collected in regard to 
having available different etiologies of diseases available for study will be essential where each 
of these may have their own unique glycan structure specific markers. It is also important to 
eliminate biases in analysis by having a sufficient number of samples from different genders and 
ethnic groups and also sufficient clinical information available to evaluate biomarker 
performance. It will also be essential to have a sufficient number of samples to run properly 
powered discovery and validation sets to assess the clinical utility of these markers. 
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DSA: Datura stramonium agglutinin; DSA-FACE: DNA sequencer–assisted fluorophore-assisted 
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immunosorbent assay; ESI: electrospray ionization; ETD: electron transfer dissociation; ETD: 
electron transfer dissociation; EThcD: Electron-Transfer/Higher-Energy Collision Dissociation; 
FLISA: fluorescence -linked immunosorbent assay; HCC: Hepatocellular Carcinoma; HCD: 
higher-energy collisional dissociation; HEDS: Hepatocellular Carcinoma Early Detection 
Strategy study; HILIC: hydrophilic interaction chromatography; Hp: Haptoglobin; IGOT: isotope-
coded glycosylation-site-specific tagging; IMS: ion mobility spectrometry; IMS-MS: ion mobility 
spectrometry-mass spectrometry; iTRAQ: Isobaric tags for relative and absolute quantitation; 
LCA: Lens culinaris agglutinin; MALDI: matrix-assisted laser desorption ionization; MRM: 
Multiple Reaction Monitoring; MS2: tandem mass spectrometry; NAFLD: non-alcoholic fatty liver 
disease; NCI: the National Cancer Institute; PGC: Porous graphitic carbon; PHA-L: Phaseolus 
vulgaris Leucoagglutinin; PRM: Parallel Reaction Monitoring; PTM: post-translational 
modification; QIT-TOF: Quadrupole ion trap-Time of Flight; SELDI-TOF-MS: surface-enhanced 
laser desorption-ionization time-of-flight mass spectrometry; TMT: tandem mass tags  
 
 
 
Table 3. Research on serum biomarkers for HCC in recent 10 years. 
Biomarker Type Methodology Ref. 
core α-1,6 
fucosylation 
2DE+MALDI-TOF MS; 
Lectin-FLISA 
(Comunale et al., 
2010) Alpha-1-antitrypsin 
(A1AT) fucosylated 
protein level 
AAL affinity chromatography+LC-
MRM-MS (Ahn et al., 2013) 
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core α-1,6 
fucosylation 
MALDI-TOF MS; 
LCA-affinity electrophoresis 
(Nakagawa et al., 
2008) 
AFP-L3% Liquid-phase binding assay (Leerapun et al., 2007) AFP-L3 
hs-AFP-L3% Microchip capillary electrophoresis; liquid-phase binding assay (Oda et al., 2011) 
AFP Fc glycopeptides LC-MS/MS-PRM (Kim et al., 2018) 
AGP multifucose index AAL affinity chromatography+LC-TOF-MS 
(Tanabe et al., 
2016) 
Apo-J β-1,4 triantennary N-glycans 
2DE+LC-MS/MS; 
Lectin-FLISA 
(Comunale et al., 
2011) 
β2-microgloblin 
(B2M) protein level SELDI-TOF-MS (Saito et al., 2010) 
Carboxylesterase 1 
(hCE1) protein level LC-MS/MS; Antibody-based assay 
(Na et al., 2009;Na 
et al., 2013) 
Ceruloplasmin core Fc ratio Endo F3+LC-MS/MS/MS (Yin et al., 2014) 
Complement C3a C3a fragment ProteinChip arrays+SELDI-MS (Kanmura et al., 2010) 
Complement factor H 
(CFH) 
site-specific core 
Fc LC-MS/MS; LC-MS-MRM 
(Benicky et al., 
2014) 
Des-gamma 
carboxyprothrombin 
(DCP) 
protein level ELISA 
(Durazo et al., 
2008;Marrero et al., 
2009) 
Fibronectin 
(FN) core Fc peptides 
iTRAQ+LCA affinity 
chromatography+LC-MS/MS (Yin et al., 2015) 
protein level 2DE; immunoblotting (Block et al., 2005) 
protein level immunoblotting 
(Marrero et al., 
2005;Mao et al., 
2010)  
protein level ELISA 
(Riener et al., 
2009;Yamamoto et 
al., 2010)  
GP73 
protein level western blotting (Hu et al., 2010) 
GP73, hemopexin, 
PIVKA-II protein level ELISA; lectin-ELISA; immunoassays (Morota et al., 2011) 
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bifucosylated N-
glycans MALDI-QIT-TOF MS (Zhu et al., 2014) 
fucosylated N-
glycans ESI-LC-MS 
(Zhang et al., 
2015b) 
Isomeric N-
glycans PGC-LC-MS/MS (Huang et al., 2017) 
Fc-Hp level Lectin-ELISA; CLEIA (Asazawa et al., 2015) 
multiply 
fucosylated 
glycopeptides 
LC-MS/MS; 
exoglycosidase/MALDI-MS/MS 
(Pompach et al., 
2013) 
multiply 
fucosylated 
glycopeptides 
LC-MS-MRM (Sanda et al., 2013) 
fucosylated N-
glycans MALDI-QIT-TOF MS (Zhang et al., 2011) 
Haptoglobin  
(Hp) 
Fc-Hp/Hp ratio magnetic beads-based lectin ELISA (Shang et al., 2017) 
Fc-Hpx Lectin-FLISA; LC-MS/MS (Comunale et al., 2009) 
 Fc-Hpx ELISA; lectin-ELISA (Kobayashi et al., 2012) 
N-glycans DSA-FACE (Debruyne et al., 2010) 
Hemopexin  
(Hpx) 
site-specific core 
Fc LC-MS/MS; LC-MS-MRM 
(Benicky et al., 
2014) 
Hp, Hpx, Kng-1, CFH site-specific core Fc LC-MS/MS; MALDI-TOF MS 
(Pompach et al., 
2014) 
HSP90 protein level 2-DE; MALDI-TOF MS (Sun et al., 2010b) 
IgGs glycoforms LC-MS-MRM (Yuan et al., 2015) 
Kininogen 
(Kng) fucosylation level Lectin-FLISA 
(Wang et al., 
2009;Wang et al., 
2017) 
Osteopontin 
(OPN) protein level LC-MS/MS; ELISA (Shang et al., 2012) 
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protein level ELISA 
(El-Din Bessa et al., 
2010;Abu El 
Makarem et al., 
2011)  
Paraoxonase-1 
(PON1) fucosylation Lectin-ELISA 
(Zhang et al., 
2015a) 
PIVKA-II protein level LC-MRM-MS (Sohn et al., 2017) 
Vimentin 
(VIM) protein level MALDI-TOF/TOF MS; ELISA (Sun et al., 2010a) 
N-glycopeptides iTRAQ+LC-MS/MS (Lee et al., 2010) 
Vitronectin  
(VTN) N-glycopeptide 
ratios TMT+LC-MS/MS (Lee et al., 2014) 
WFA+-M2BP GalNAc residues lectin-antibody sandwich immunoassay 
(Yamasaki et al., 
2014) 
core Fc 
glycopeptides LC-MS-MRM (Ma et al., 2018) 
core Fc 
glycopeptides LC-MS/MS/MS; LC-MRM-MS (Zhao et al., 2011) 
S90K, IGFBP-3, 
and TSP-1 LC-MS/MS; ELISA (Chen et al., 2011) 
C3, CE, HRG, 
CD14, and HGF 
lectin affinity chromatography + LC-
MS/MS; lectin-Ab arrays (Liu et al., 2010) 
CP, ACT, and 
MMRN1 2D LC-MALDI-MS 
(Ishihara et al., 
2011) 
A1AG1, AACT, 
A1AT, and CERU 
AAL affinity chromatography + LC-
MRM-MS (Ahn et al., 2012) 
N-glycans LC-ESI-MS (Tsai et al., 2014) 
G2890 and 
G3560 N-glycans MALDI-TOF/TOF 
(Kamiyama et al., 
2013) 
glycoproteins/ N-
glycans 
LC-ESI-MS/MS; MALDI-TOF/TOF-
MS (Yang et al., 2013) 
PHA-L reactive 
glycoproteins 
PHA-L affinity chromatography+LC-
MS/MS  (Liu et al., 2017b) 
global serum profiling 
branch α(1,3)-
fucosylated N-
glycans 
DSA-FACE (Liu et al., 2007) 
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N-glycans MALDI-TOF-MS (Tang et al., 2010) 
N-glycans HPLC; Lectin-FLISA (Comunale et al., 2013) 
N-glycans MALDI-TOF/TOF MS (Goldman et al., 2009) 
isomeric N-
glycans IMS-MS 
(Isailovic et al., 
2008;Isailovic et al., 
2012) 
 
outer arm 
fucosylated N-
glycans 
LC-MS (Tanabe et al., 2008) 
peptide and 
glycan panel MALDI-TOF/TOF MS 
(Ressom et al., 
2008) 
peptides MALDI-TOF/TOF MS (Goldman et al., 2007) 
glycoprotein 
proflie lectin coupled IGOT-LC-MS/MS (Kaji et al., 2013) 
protein profile 2DE+LC-MS/MS (Yang et al., 2007) 
protein profile SELDI-TOF-MS (Cui et al., 2007) 
 
protein profile 2DE+MALDI-TOF-MS (Wu et al., 2012) 
AAL, Aleuria aurantia lectin 
CLEIA, chemiluminescent enzyme immunoassay 
Core Fc, core fucosylation  
DSA-FACE, DNA sequencer–assisted fluorophore-assisted carbohydrate electrophoresis 
ELISA, enzyme linked immunosorbent assay 
Fc-Hp, fucosylated haptoglobin 
Fc-Hpx, fucosylated hemopexin 
IGOT, isotope-coded glycosylation site-specific tagging 
IMS-MS, ion mobility spectrometry-mass spectrometry 
iTRAQ, isobaric tags for relative and absolute quantitation 
LCA, Lens culinaris agglutinin 
lectin-FLISA, Lectin fluoropore-linked immunosorbent assay 
MRM, multiple reaction monitoring 
PHA-L, Phaseolus vulgaris Leucoagglutinin 
SELDI-TOF-MS, surface-enhanced laser desorption-ionization time-of-flight mass spectrometry 
TMT, tandem mass tags 
WFA+-M2BP, Wisteria floribunda agglutinin-positive human Mac-2 binding protein 
 
References 
Au
tho
r M
an
us
cri
pt
Abu El Makarem, M.A., Abdel-Aleem, A., Ali, A., Saber, R., Shatat, M., Rahem, D.A., and Sayed, D. (2011). 
Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular 
carcinoma. Ann Hepatol 10, 296-305. 
Ahn, Y.H., Lee, J.Y., Lee, J.Y., Kim, Y.S., Ko, J.H., and Yoo, J.S. (2009). Quantitative analysis of an aberrant 
glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM 
mass spectrometry. J Proteome Res 8, 4216-4224. 
Ahn, Y.H., Shin, P.M., Kim, Y.S., Oh, N.R., Ji, E.S., Kim, K.H., Lee, Y.J., Kim, S.H., and Yoo, J.S. (2013). 
Quantitative analysis of aberrant protein glycosylation in liver cancer plasma by AAL-enrichment 
and MRM mass spectrometry. Analyst 138, 6454-6462. 
Ahn, Y.H., Shin, P.M., Oh, N.R., Park, G.W., Kim, H., and Yoo, J.S. (2012). A lectin-coupled, targeted 
proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer 
biomarkers in human plasma. J Proteomics 75, 5507-5515. 
Alley, W.R., Jr., Mechref, Y., and Novotny, M.V. (2009). Characterization of glycopeptides by combining 
collision-induced dissociation and electron-transfer dissociation mass spectrometry data. Rapid 
Commun Mass Spectrom 23, 161-170. 
An, H.J., Froehlich, J.W., and Lebrilla, C.B. (2009). Determination of glycosylation sites and site-specific 
heterogeneity in glycoproteins. Curr Opin Chem Biol 13, 421-426. 
Apweiler, R., Hermjakob, H., and Sharon, N. (1999). On the frequency of protein glycosylation, as 
deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1473, 4-8. 
Asazawa, H., Kamada, Y., Takeda, Y., Takamatsu, S., Shinzaki, S., Kim, Y., Nezu, R., Kuzushita, N., Mita, E., 
Kato, M., and Miyoshi, E. (2015). Serum fucosylated haptoglobin in chronic liver diseases as a 
potential biomarker of hepatocellular carcinoma development. Clin Chem Lab Med 53, 95-102. 
Benicky, J., Sanda, M., Pompach, P., Wu, J., and Goldman, R. (2014). Quantification of fucosylated 
hemopexin and complement factor H in plasma of patients with liver disease. Anal Chem 86, 
10716-10723. 
Bern, M., Kil, Y.J., and Becker, C. (2012). Byonic: advanced peptide and protein identification software. 
Curr Protoc Bioinformatics Chapter 13, Unit13 20. 
Block, T.M., Comunale, M.A., Lowman, M., Steel, L.F., Romano, P.R., Fimmel, C., Tennant, B.C., London, 
W.T., Evans, A.A., Blumberg, B.S., Dwek, R.A., Mattu, T.S., and Mehta, A.S. (2005). Use of 
targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in 
woodchucks and humans. Proc Natl Acad Sci U S A 102, 779-784. 
Bruix, J., Sherman, M., and American Association for the Study of Liver, D. (2011). Management of 
hepatocellular carcinoma: an update. Hepatology 53, 1020-1022. 
Bruix, J., Sherman, M., and Practice Guidelines Committee, A.a.F.T.S.O.L.D. (2005). Management of 
hepatocellular carcinoma. Hepatology 42, 1208-1236. 
Chandler, K.B., Pompach, P., Goldman, R., and Edwards, N. (2013). Exploring site-specific N-glycosylation 
microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan 
database search. J Proteome Res 12, 3652-3666. 
Chen, J., Shah, P., and Zhang, H. (2013). Solid phase extraction of N-linked glycopeptides using hydrazide 
tip. Anal Chem 85, 10670-10674. 
Chen, R., Tan, Y., Wang, M., Wang, F., Yao, Z., Dong, L., Ye, M., Wang, H., and Zou, H. (2011). 
Development of glycoprotein capture-based label-free method for the high-throughput 
screening of differential glycoproteins in hepatocellular carcinoma. Mol Cell Proteomics 10, 
M110 006445. 
Chen, Z., Glover, M.S., and Li, L. (2017a). Recent advances in ion mobility-mass spectrometry for 
improved structural characterization of glycans and glycoconjugates. Curr Opin Chem Biol 42, 1-
8. 
Au
tho
r M
an
us
cri
pt
Chen, Z., Yu, Q., Hao, L., Liu, F., Johnson, J., Tian, Z., Kao, W.J., Xu, W., and Li, L. (2018). Site-specific 
characterization and quantitation of N-glycopeptides in PKM2 knockout breast cancer cells using 
DiLeu isobaric tags enabled by electron-transfer/higher-energy collision dissociation (EThcD). 
Analyst 143, 2508-2519. 
Chen, Z., Zhong, X., Tie, C., Chen, B., Zhang, X., and Li, L. (2017b). Development of a hydrophilic 
interaction liquid chromatography coupled with matrix-assisted laser desorption/ionization-
mass spectrometric imaging platform for N-glycan relative quantitation using stable-isotope 
labeled hydrazide reagents. Anal Bioanal Chem 409, 4437-4447. 
Clark, D., and Mao, L. (2012). Cancer biomarker discovery: lectin-based strategies targeting 
glycoproteins. Dis Markers 33, 1-10. 
Comunale, M.A., Lowman, M., Long, R.E., Krakover, J., Philip, R., Seeholzer, S., Evans, A.A., Hann, H.W., 
Block, T.M., and Mehta, A.S. (2006). Proteomic analysis of serum associated fucosylated 
glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 5, 308-
315. 
Comunale, M.A., Rodemich-Betesh, L., Hafner, J., Wang, M., Norton, P., Di Bisceglie, A.M., Block, T., and 
Mehta, A. (2010). Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer 
patients: implications for a biomarker of hepatocellular carcinoma. PLoS One 5, e12419. 
Comunale, M.A., Wang, M., Anbarasan, N., Betesh, L., Karabudak, A., Moritz, E., Devarajan, K., Marrero, 
J., Block, T.M., and Mehta, A. (2013). Total serum glycan analysis is superior to lectin-FLISA for 
the early detection of hepatocellular carcinoma. Proteomics Clin Appl 7, 690-700. 
Comunale, M.A., Wang, M., Hafner, J., Krakover, J., Rodemich, L., Kopenhaver, B., Long, R.E., Junaidi, O., 
Bisceglie, A.M., Block, T.M., and Mehta, A.S. (2009). Identification and development of 
fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 8, 
595-602. 
Comunale, M.A., Wang, M., Rodemich-Betesh, L., Hafner, J., Lamontagne, A., Klein, A., Marrero, J., Di 
Bisceglie, A.M., Gish, R., Block, T., and Mehta, A. (2011). Novel changes in glycosylation of serum 
Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 20, 1222-
1229. 
Cui, J., Kang, X., Dai, Z., Huang, C., Zhou, H., Guo, K., Li, Y., Zhang, Y., Sun, R., Chen, J., Li, Y., Tang, Z., 
Uemura, T., and Liu, Y. (2007). Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular 
carcinoma by SELDI-based serum decision tree classification. J Cancer Res Clin Oncol 133, 825-
834. 
Dai, Z., Zhou, J., Qiu, S.J., Liu, Y.K., and Fan, J. (2009). Lectin-based glycoproteomics to explore and 
analyze hepatocellular carcinoma-related glycoprotein markers. Electrophoresis 30, 2957-2966. 
Debruyne, E.N., Vanderschaeghe, D., Van Vlierberghe, H., Vanhecke, A., Callewaert, N., and Delanghe, 
J.R. (2010). Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma 
patients. Clin Chem 56, 823-831. 
Dube, D.H., and Bertozzi, C.R. (2005). Glycans in cancer and inflammation--potential for therapeutics 
and diagnostics. Nat Rev Drug Discov 4, 477-488. 
Durazo, F.A., Blatt, L.M., Corey, W.G., Lin, J.H., Han, S., Saab, S., Busuttil, R.W., and Tong, M.J. (2008). 
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic 
hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 23, 1541-1548. 
El-Din Bessa, S.S., Elwan, N.M., Suliman, G.A., and El-Shourbagy, S.H. (2010). Clinical significance of 
plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular 
carcinoma. Arch Med Res 41, 541-547. 
El-Serag, H.B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 
142, 1264-1273 e1261. 
Au
tho
r M
an
us
cri
pt
Flores, A., and Marrero, J.A. (2014). Emerging trends in hepatocellular carcinoma: focus on diagnosis and 
therapeutics. Clin Med Insights Oncol 8, 71-76. 
Frese, C.K., Altelaar, A.F., Van Den Toorn, H., Nolting, D., Griep-Raming, J., Heck, A.J., and Mohammed, S. 
(2012). Toward full peptide sequence coverage by dual fragmentation combining electron-
transfer and higher-energy collision dissociation tandem mass spectrometry. Anal Chem 84, 
9668-9673. 
Fukuyama, Y., Nakaya, S., Yamazaki, Y., and Tanaka, K. (2008). Ionic liquid matrixes optimized for MALDI-
MS of sulfated/sialylated/neutral oligosaccharides and glycopeptides. Anal Chem 80, 2171-2179. 
Fuster, M.M., and Esko, J.D. (2005). The sweet and sour of cancer: glycans as novel therapeutic targets. 
Nat Rev Cancer 5, 526-542. 
Gaye, M.M., Valentine, S.J., Hu, Y., Mirjankar, N., Hammoud, Z.T., Mechref, Y., Lavine, B.K., and 
Clemmer, D.E. (2012). Ion mobility-mass spectrometry analysis of serum N-linked glycans from 
esophageal adenocarcinoma phenotypes. J Proteome Res 11, 6102-6110. 
Glover, M.S., Yu, Q., Chen, Z., Shi, X., Kent, K.C., and Li, L. (2018). Characterization of intact sialylated 
glycopeptides and phosphorylated glycopeptides from IMAC enriched samples by EThcD 
fragmentation: Toward combining phosphoproteomics and glycoproteomics. International 
Journal of Mass Spectrometry 427, 35-42. 
Goldman, R., Ressom, H.W., Abdel-Hamid, M., Goldman, L., Wang, A., Varghese, R.S., An, Y., Loffredo, 
C.A., Drake, S.K., Eissa, S.A., Gouda, I., Ezzat, S., and Moiseiwitsch, F.S. (2007). Candidate 
markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of 
serum. Carcinogenesis 28, 2149-2153. 
Goldman, R., Ressom, H.W., Varghese, R.S., Goldman, L., Bascug, G., Loffredo, C.A., Abdel-Hamid, M., 
Gouda, I., Ezzat, S., Kyselova, Z., Mechref, Y., and Novotny, M.V. (2009). Detection of 
hepatocellular carcinoma using glycomic analysis. Clin Cancer Res 15, 1808-1813. 
Hanley, J.A., and Mcneil, B.J. (1982). The meaning and use of the area under a receiver operating 
characteristic (ROC) curve. Radiology 143, 29-36. 
Hu, J.S., Wu, D.W., Liang, S., and Miao, X.Y. (2010). GP73, a resident Golgi glycoprotein, is sensibility and 
specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. 
Med Oncol 27, 339-345. 
Hua, S., An, H.J., Ozcan, S., Ro, G.S., Soares, S., Devere-White, R., and Lebrilla, C.B. (2011). 
Comprehensive native glycan profiling with isomer separation and quantitation for the discovery 
of cancer biomarkers. Analyst 136, 3663-3671. 
Huang, Y., Zhou, S., Zhu, J., Lubman, D.M., and Mechref, Y. (2017). LC-MS/MS isomeric profiling of 
permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) 
and cirrhotic patients. Electrophoresis 38, 2160-2167. 
Ioannou, G.N., Green, P., Lowy, E., Mun, E.J., and Berry, K. (2018). Differences in hepatocellular 
carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS One 13, 
e0204412. 
Isailovic, D., Kurulugama, R.T., Plasencia, M.D., Stokes, S.T., Kyselova, Z., Goldman, R., Mechref, Y., 
Novotny, M.V., and Clemmer, D.E. (2008). Profiling of human serum glycans associated with liver 
cancer and cirrhosis by IMS-MS. J Proteome Res 7, 1109-1117. 
Isailovic, D., Plasencia, M.D., Gaye, M.M., Stokes, S.T., Kurulugama, R.T., Pungpapong, V., Zhang, M., 
Kyselova, Z., Goldman, R., Mechref, Y., Novotny, M.V., and Clemmer, D.E. (2012). Delineating 
diseases by IMS-MS profiling of serum N-linked glycans. J Proteome Res 11, 576-585. 
Ishihara, T., Fukuda, I., Morita, A., Takinami, Y., Okamoto, H., Nishimura, S., and Numata, Y. (2011). 
Development of quantitative plasma N-glycoproteomics using label-free 2-D LC-MALDI MS and 
its applicability for biomarker discovery in hepatocellular carcinoma. J Proteomics 74, 2159-
2168. 
Au
tho
r M
an
us
cri
pt
Kailemia, M.J., Park, D., and Lebrilla, C.B. (2017). Glycans and glycoproteins as specific biomarkers for 
cancer. Anal Bioanal Chem 409, 395-410. 
Kailemia, M.J., Ruhaak, L.R., Lebrilla, C.B., and Amster, I.J. (2014). Oligosaccharide analysis by mass 
spectrometry: a review of recent developments. Anal Chem 86, 196-212. 
Kaji, H., Ocho, M., Togayachi, A., Kuno, A., Sogabe, M., Ohkura, T., Nozaki, H., Angata, T., Chiba, Y., Ozaki, 
H., Hirabayashi, J., Tanaka, Y., Mizokami, M., Ikehara, Y., and Narimatsu, H. (2013). 
Glycoproteomic discovery of serological biomarker candidates for HCV/HBV infection-associated 
liver fibrosis and hepatocellular carcinoma. J Proteome Res 12, 2630-2640. 
Kamiyama, T., Yokoo, H., Furukawa, J., Kurogochi, M., Togashi, T., Miura, N., Nakanishi, K., Kamachi, H., 
Kakisaka, T., Tsuruga, Y., Fujiyoshi, M., Taketomi, A., Nishimura, S., and Todo, S. (2013). 
Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. 
Hepatology 57, 2314-2325. 
Kanmura, S., Uto, H., Sato, Y., Kumagai, K., Sasaki, F., Moriuchi, A., Oketani, M., Ido, A., Nagata, K., 
Hayashi, K., Stuver, S.O., and Tsubouchi, H. (2010). The complement component C3a fragment is 
a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 45, 
459-467. 
Kanwal, F., Hoang, T., Kramer, J.R., Asch, S.M., Goetz, M.B., Zeringue, A., Richardson, P., and El-Serag, 
H.B. (2011). Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus 
infection. Gastroenterology 140, 1182-1188 e1181. 
Kanwal, F., Kramer, J.R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P.A., Li, L., 
Desiderio, R., Thrift, A.P., Asch, S.M., Chu, J., and El-Serag, H.B. (2018). Risk of Hepatocellular 
Cancer in Patients with Non-alcoholic Fatty Liver Disease. Gastroenterology. 
Kim, K., Ruhaak, L.R., Nguyen, U.T., Taylor, S.L., Dimapasoc, L., Williams, C., Stroble, C., Ozcan, S., 
Miyamoto, S., Lebrilla, C.B., and Leiserowitz, G.S. (2014). Evaluation of glycomic profiling as a 
diagnostic biomarker for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 23, 611-
621. 
Kim, K.H., Lee, S.Y., Hwang, H., Lee, J.Y., Ji, E.S., An, H.J., Kim, J.Y., and Yoo, J.S. (2018). Direct Monitoring 
of Fucosylated Glycopeptides of Alpha-fetoprotein in Human Serum for Early Hepatocellular 
Carcinoma by Liquid Chromatography-Tandem Mass Spectrometry with Immunoprecipitation. 
Proteomics Clin Appl, e1800062. 
Kinoshita, N., Ohno, M., Nishiura, T., Fujii, S., Nishikawa, A., Kawakami, Y., Uozumi, N., and Taniguchi, N. 
(1991). Glycosylation at the Fab portion of myeloma immunoglobulin G and increased 
fucosylated biantennary sugar chains: structural analysis by high-performance liquid 
chromatography and antibody-lectin enzyme immunoassay using Lens culinaris agglutinin. 
Cancer Res 51, 5888-5892. 
Kobayashi, S., Nouso, K., Kinugasa, H., Takeuchi, Y., Tomoda, T., Miyahara, K., Hagihara, H., Kuwaki, K., 
Onishi, H., Nakamura, S., Ikeda, F., Miyake, Y., Shiraha, H., Takaki, A., and Yamamoto, K. (2012). 
Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular 
carcinoma. Hepatol Res 42, 1187-1195. 
Lee, H.J., Cha, H.J., Lim, J.S., Lee, S.H., Song, S.Y., Kim, H., Hancock, W.S., Yoo, J.S., and Paik, Y.K. (2014). 
Abundance-ratio-based semiquantitative analysis of site-specific N-linked glycopeptides present 
in the plasma of hepatocellular carcinoma patients. J Proteome Res 13, 2328-2338. 
Lee, H.J., Na, K., Choi, E.Y., Kim, K.S., Kim, H., and Paik, Y.K. (2010). Simple method for quantitative 
analysis of N-linked glycoproteins in hepatocellular carcinoma specimens. J Proteome Res 9, 
308-318. 
Lee, J., Hua, S., Lee, S.H., Oh, M.J., Yun, J., Kim, J.Y., Kim, J.H., Kim, J.H., and An, H.J. (2018). Designation 
of fingerprint glycopeptides for targeted glycoproteomic analysis of serum haptoglobin: insights 
into gastric cancer biomarker discovery. Anal Bioanal Chem 410, 1617-1629. 
Au
tho
r M
an
us
cri
pt
Lee, J.Y., Lee, H.K., Park, G.W., Hwang, H., Jeong, H.K., Yun, K.N., Ji, E.S., Kim, K.H., Kim, J.S., Kim, J.W., 
Yun, S.H., Choi, C.W., Kim, S.I., Lim, J.S., Jeong, S.K., Paik, Y.K., Lee, S.Y., Park, J., Kim, S.Y., Choi, 
Y.J., Kim, Y.I., Seo, J., Cho, J.Y., Oh, M.J., Seo, N., An, H.J., Kim, J.Y., and Yoo, J.S. (2016). 
Characterization of Site-Specific N-Glycopeptide Isoforms of alpha-1-Acid Glycoprotein from an 
Interlaboratory Study Using LC-MS/MS. J Proteome Res 15, 4146-4164. 
Leerapun, A., Suravarapu, S.V., Bida, J.P., Clark, R.J., Sanders, E.L., Mettler, T.A., Stadheim, L.M., Aderca, 
I., Moser, C.D., Nagorney, D.M., Larusso, N.F., De Groen, P.C., Menon, K.V., Lazaridis, K.N., 
Gores, G.J., Charlton, M.R., Roberts, R.O., Therneau, T.M., Katzmann, J.A., and Roberts, L.R. 
(2007). The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of 
hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol 
Hepatol 5, 394-402; quiz 267. 
Leiserowitz, G.S., Lebrilla, C., Miyamoto, S., An, H.J., Duong, H., Kirmiz, C., Li, B., Liu, H., and Lam, K.S. 
(2008). Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int J Gynecol 
Cancer 18, 470-475. 
Li, D., Mallory, T., and Satomura, S. (2001). AFP-L3: a new generation of tumor marker for hepatocellular 
carcinoma. Clin Chim Acta 313, 15-19. 
Liang, J., Zhu, J., Wang, M., Zhang, J., Parikh, N., Liu, S., and Lubman, D.M. Evaluation of AGP fucosylation 
as a marker for hepatocellular carcinoma. (manuscript in preparation). 
Lin, Z., Simeone, D.M., Anderson, M.A., Brand, R.E., Xie, X., Shedden, K.A., Ruffin, M.T., and Lubman, 
D.M. (2011). Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic 
cancer. J Proteome Res 10, 2602-2611. 
Liu, M.Q., Zeng, W.F., Fang, P., Cao, W.Q., Liu, C., Yan, G.Q., Zhang, Y., Peng, C., Wu, J.Q., Zhang, X.J., Tu, 
H.J., Chi, H., Sun, R.X., Cao, Y., Dong, M.Q., Jiang, B.Y., Huang, J.M., Shen, H.L., Wong, C.C.L., He, 
S.M., and Yang, P.Y. (2017a). pGlyco 2.0 enables precision N-glycoproteomics with 
comprehensive quality control and one-step mass spectrometry for intact glycopeptide 
identification. Nat Commun 8, 438. 
Liu, T., Shang, S., Li, W., Qin, X., Sun, L., Zhang, S., and Liu, Y. (2017b). Assessment of Hepatocellular 
Carcinoma Metastasis Glycobiomarkers Using Advanced Quantitative N-glycoproteome Analysis. 
Front Physiol 8, 472. 
Liu, X.E., Desmyter, L., Gao, C.F., Laroy, W., Dewaele, S., Vanhooren, V., Wang, L., Zhuang, H., Callewaert, 
N., Libert, C., Contreras, R., and Chen, C. (2007). N-glycomic changes in hepatocellular carcinoma 
patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46, 1426-1435. 
Liu, Y., He, J., Li, C., Benitez, R., Fu, S., Marrero, J., and Lubman, D.M. (2010). Identification and 
confirmation of biomarkers using an integrated platform for quantitative analysis of 
glycoproteins and their glycosylations. J Proteome Res 9, 798-805. 
Liu, Y., He, J., and Lubman, D.M. (2013). Characterization of membrane-associated glycoproteins using 
lectin affinity chromatography and mass spectrometry. Methods Mol Biol 951, 69-77. 
Ma, J., Sanda, M., Wei, R., Zhang, L., and Goldman, R. (2018). Quantitative analysis of core fucosylation 
of serum proteins in liver diseases by LC-MS-MRM. J Proteomics, doi: 
10.1016/j.jprot.2018.1002.1003. 
Mao, Y., Yang, H., Xu, H., Lu, X., Sang, X., Du, S., Zhao, H., Chen, W., Xu, Y., Chi, T., Yang, Z., Cai, J., Li, H., 
Chen, J., Zhong, S., Mohanti, S.R., Lopez-Soler, R., Millis, J.M., Huang, J., and Zhang, H. (2010). 
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 59, 
1687-1693. 
Marrero, J.A., Feng, Z., Wang, Y., Nguyen, M.H., Befeler, A.S., Roberts, L.R., Reddy, K.R., Harnois, D., 
Llovet, J.M., Normolle, D., Dalhgren, J., Chia, D., Lok, A.S., Wagner, P.D., Srivastava, S., and 
Schwartz, M. (2009). Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound 
alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137, 110-118. 
Au
tho
r M
an
us
cri
pt
Marrero, J.A., and Henley, K.S. (2011). The role of serum biomarkers in hepatocellular carcinoma 
surveillance. Gastroenterol Hepatol (N Y) 7, 821-823. 
Marrero, J.A., Romano, P.R., Nikolaeva, O., Steel, L., Mehta, A., Fimmel, C.J., Comunale, M.A., D'amelio, 
A., Lok, A.S., and Block, T.M. (2005). GP73, a resident Golgi glycoprotein, is a novel serum 
marker for hepatocellular carcinoma. J Hepatol 43, 1007-1012. 
Meany, D.L., and Chan, D.W. (2011). Aberrant glycosylation associated with enzymes as cancer 
biomarkers. Clin Proteomics 8, 7. 
Mechref, Y. (2012). Use of CID/ETD mass spectrometry to analyze glycopeptides. Curr Protoc Protein Sci 
Chapter 12, Unit 12 11 11-11. 
Mehta, A., and Block, T.M. (2008). Fucosylated glycoproteins as markers of liver disease. Dis Markers 25, 
259-265. 
Mehta, A., Herrera, H., and Block, T. (2015). Glycosylation and liver cancer. Adv Cancer Res 126, 257-279. 
Michael, S.M., Chien, M., and Lubman, D.M. (1992). An Ion Trap Storage Time-of-Flight Mass-
Spectrometer. Review of Scientific Instruments 63, 4277-4284. 
Miyoshi, E., Moriwaki, K., and Nakagawa, T. (2008). Biological function of fucosylation in cancer biology. 
J Biochem 143, 725-729. 
Miyoshi, E., Moriwaki, K., Terao, N., Tan, C.C., Terao, M., Nakagawa, T., Matsumoto, H., Shinzaki, S., and 
Kamada, Y. (2012). Fucosylation is a promising target for cancer diagnosis and therapy. 
Biomolecules 2, 34-45. 
Morota, K., Nakagawa, M., Sekiya, R., Hemken, P.M., Sokoll, L.J., Elliott, D., Chan, D.W., and Dowell, B.L. 
(2011). A comparative evaluation of Golgi protein-73, fucosylated hemopexin, alpha-
fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma. Clin Chem Lab Med 49, 711-718. 
Munkley, J., and Elliott, D.J. (2016). Hallmarks of glycosylation in cancer. Oncotarget 7, 35478-35489. 
Na, K., Jeong, S.K., Lee, M.J., Cho, S.Y., Kim, S.A., Lee, M.J., Song, S.Y., Kim, H., Kim, K.S., Lee, H.W., and 
Paik, Y.K. (2013). Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to 
discriminate hepatocellular carcinoma from other liver diseases in Korean patients. Int J Cancer 
133, 408-415. 
Na, K., Lee, E.Y., Lee, H.J., Kim, K.Y., Lee, H., Jeong, S.K., Jeong, A.S., Cho, S.Y., Kim, S.A., Song, S.Y., Kim, 
K.S., Cho, S.W., Kim, H., and Paik, Y.K. (2009). Human plasma carboxylesterase 1, a novel 
serologic biomarker candidate for hepatocellular carcinoma. Proteomics 9, 3989-3999. 
Nakagawa, T., Miyoshi, E., Yakushijin, T., Hiramatsu, N., Igura, T., Hayashi, N., Taniguchi, N., and Kondo, 
A. (2008). Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular 
carcinoma patients. J Proteome Res 7, 2222-2233. 
Nishikaze, T. (2017). Sensitive and Structure-Informative N-Glycosylation Analysis by MALDI-MS; 
Ionization, Fragmentation, and Derivatization. Mass Spectrom (Tokyo) 6, A0060. 
Oda, K., Ido, A., Tamai, T., Matsushita, M., Kumagai, K., Mawatari, S., Saishoji, A., Kure, T., Ohno, K., 
Toyokura, E., Imanaka, D., Moriuchi, A., Uto, H., Oketani, M., Hashiguchi, T., and Tsubouchi, H. 
(2011). Highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein is useful for early 
detection of hepatocellular carcinoma in patients with chronic liver disease. Oncol Rep 26, 1227-
1233. 
Patwa, T., Li, C., Simeone, D.M., and Lubman, D.M. (2010). Glycoprotein analysis using protein 
microarrays and mass spectrometry. Mass Spectrom Rev 29, 830-844. 
Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J., and Bell, B.P. (2006). The contributions of 
hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. 
J Hepatol 45, 529-538. 
Pinho, S.S., and Reis, C.A. (2015). Glycosylation in cancer: mechanisms and clinical implications. Nat Rev 
Cancer 15, 540-555. 
Au
tho
r M
an
us
cri
pt
Pompach, P., Ashline, D.J., Brnakova, Z., Benicky, J., Sanda, M., and Goldman, R. (2014). Protein and site 
specificity of fucosylation in liver-secreted glycoproteins. J Proteome Res 13, 5561-5569. 
Pompach, P., Brnakova, Z., Sanda, M., Wu, J., Edwards, N., and Goldman, R. (2013). Site-specific 
glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol Cell Proteomics 
12, 1281-1293. 
Powers, T.W., Holst, S., Wuhrer, M., Mehta, A.S., and Drake, R.R. (2015). Two-Dimensional N-Glycan 
Distribution Mapping of Hepatocellular Carcinoma Tissues by MALDI-Imaging Mass 
Spectrometry. Biomolecules 5, 2554-2572. 
Ressom, H.W., Varghese, R.S., Goldman, L., An, Y., Loffredo, C.A., Abdel-Hamid, M., Kyselova, Z., 
Mechref, Y., Novotny, M., Drake, S.K., and Goldman, R. (2008). Analysis of MALDI-TOF mass 
spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J 
Proteome Res 7, 603-610. 
Riener, M.O., Stenner, F., Liewen, H., Soll, C., Breitenstein, S., Pestalozzi, B.C., Samaras, P., Probst-
Hensch, N., Hellerbrand, C., Mullhaupt, B., Clavien, P.A., Bahra, M., Neuhaus, P., Wild, P., 
Fritzsche, F., Moch, H., Jochum, W., and Kristiansen, G. (2009). Golgi phosphoprotein 2 
(GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular 
carcinomas. Hepatology 49, 1602-1609. 
Ruhaak, L.R., and Lebrilla, C.B. (2015). Applications of Multiple Reaction Monitoring to Clinical 
Glycomics. Chromatographia 78, 335-342. 
Saito, Y., Oba, N., Nishinakagawa, S., Mizuguchi, Y., Kojima, T., Nomura, K., and Nakatsura, T. (2010). 
Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible 
hepatocellular carcinoma in patient with liver cirrhosis. Oncol Rep 23, 1325-1330. 
Sanda, M., Pompach, P., Brnakova, Z., Wu, J., Makambi, K., and Goldman, R. (2013). Quantitative liquid 
chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-
specific glycoforms of haptoglobin in liver disease. Mol Cell Proteomics 12, 1294-1305. 
Segu, Z.M., and Mechref, Y. (2010). Characterizing protein glycosylation sites through higher-energy C-
trap dissociation. Rapid Commun Mass Spectrom 24, 1217-1225. 
Selman, M.H., Hemayatkar, M., Deelder, A.M., and Wuhrer, M. (2011). Cotton HILIC SPE microtips for 
microscale purification and enrichment of glycans and glycopeptides. Anal Chem 83, 2492-2499. 
Shang, S., Li, W., Qin, X., Zhang, S., and Liu, Y. (2017). Aided Diagnosis of Hepatocellular Carcinoma Using 
Serum Fucosylated Haptoglobin Ratios. J Cancer 8, 887-893. 
Shang, S., Plymoth, A., Ge, S., Feng, Z., Rosen, H.R., Sangrajrang, S., Hainaut, P., Marrero, J.A., and 
Beretta, L. (2012). Identification of osteopontin as a novel marker for early hepatocellular 
carcinoma. Hepatology 55, 483-490. 
Singal, A.G., Conjeevaram, H.S., Volk, M.L., Fu, S., Fontana, R.J., Askari, F., Su, G.L., Lok, A.S., and 
Marrero, J.A. (2012). Effectiveness of hepatocellular carcinoma surveillance in patients with 
cirrhosis. Cancer Epidemiol Biomarkers Prev 21, 793-799. 
Sohn, A., Kim, H., Yu, S.J., Yoon, J.H., and Kim, Y. (2017). A quantitative analytical method for PIVKA-II 
using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular 
carcinoma. Anal Bioanal Chem 409, 2829-2838. 
Song, E., Pyreddy, S., and Mechref, Y. (2012). Quantification of glycopeptides by multiple reaction 
monitoring liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 
26, 1941-1954. 
Stowell, S.R., Ju, T., and Cummings, R.D. (2015). Protein glycosylation in cancer. Annu Rev Pathol 10, 
473-510. 
Sun, S., Poon, R.T., Lee, N.P., Yeung, C., Chan, K.L., Ng, I.O., Day, P.J., and Luk, J.M. (2010a). Proteomics 
of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). 
J Proteome Res 9, 1923-1930. 
Au
tho
r M
an
us
cri
pt
Sun, Y., Zang, Z., Xu, X., Zhang, Z., Zhong, L., Zan, W., Zhao, Y., and Sun, L. (2010b). Differential 
proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by 
two-dimensional electrophoresis and mass spectrometry. Int J Mol Sci 11, 1423-1433. 
Tanabe, K., Deguchi, A., Higashi, M., Usuki, H., Suzuki, Y., Uchimura, Y., Kuriyama, S., and Ikenaka, K. 
(2008). Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma 
patients. Biochem Biophys Res Commun 374, 219-225. 
Tanabe, K., Kitagawa, K., Kojima, N., and Iijima, S. (2016). Multifucosylated Alpha-1-acid Glycoprotein as 
a Novel Marker for Hepatocellular Carcinoma. J Proteome Res 15, 2935-2944. 
Tang, Z., Varghese, R.S., Bekesova, S., Loffredo, C.A., Hamid, M.A., Kyselova, Z., Mechref, Y., Novotny, 
M.V., Goldman, R., and Ressom, H.W. (2010). Identification of N-glycan serum markers 
associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res 9, 104-
112. 
Tie, C., and Zhang, X.X. (2012). A new labelling reagent for glycans analysis by capillary electrophoresis-
mass spectrometry. Analytical Methods 4, 357-359. 
Trevisani, F., D'intino, P.E., Morselli-Labate, A.M., Mazzella, G., Accogli, E., Caraceni, P., Domenicali, M., 
De Notariis, S., Roda, E., and Bernardi, M. (2001). Serum alpha-fetoprotein for diagnosis of 
hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV 
status. J Hepatol 34, 570-575. 
Tsai, T.H., Wang, M., Di Poto, C., Hu, Y., Zhou, S., Zhao, Y., Varghese, R.S., Luo, Y., Tadesse, M.G., Ziada, 
D.H., Desai, C.S., Shetty, K., Mechref, Y., and Ressom, H.W. (2014). LC-MS profiling of N-Glycans 
derived from human serum samples for biomarker discovery in hepatocellular carcinoma. J 
Proteome Res 13, 4859-4868. 
Varadi, C., Mittermayr, S., Szekrenyes, A., Kadas, J., Takacs, L., Kurucz, I., and Guttman, A. (2013). 
Analysis of haptoglobin N-glycome alterations in inflammatory and malignant lung diseases by 
capillary electrophoresis. Electrophoresis 34, 2287-2294. 
Wang, M., Long, R.E., Comunale, M.A., Junaidi, O., Marrero, J., Di Bisceglie, A.M., Block, T.M., and 
Mehta, A.S. (2009). Novel fucosylated biomarkers for the early detection of hepatocellular 
carcinoma. Cancer Epidemiol Biomarkers Prev 18, 1914-1921. 
Wang, M., Sanda, M., Comunale, M.A., Herrera, H., Swindell, C., Kono, Y., Singal, A.G., Marrero, J., Block, 
T., Goldman, R., and Mehta, A. (2017). Changes in the Glycosylation of Kininogen and the 
Development of a Kininogen-Based Algorithm for the Early Detection of HCC. Cancer Epidemiol 
Biomarkers Prev 26, 795-803. 
Wang, M., Zhu, J., Liang, J., Gao, C., and Lubman, D.M. N-glycomic changes in serum immunoglobulins 
between hepatocellular carcinoma and liver cirrhosis. (manuscript in preparation). 
Wang, Y., Ao, X., Vuong, H., Konanur, M., Miller, F.R., Goodison, S., and Lubman, D.M. (2008). 
Membrane glycoproteins associated with breast tumor cell progression identified by a lectin 
affinity approach. J Proteome Res 7, 4313-4325. 
West, C.A., Wang, M., Herrera, H., Liang, H., Black, A., Angel, P.M., Drake, R.R., and Mehta, A.S. (2018). 
N-Linked Glycan Branching and Fucosylation Are Increased Directly in Hcc Tissue As Determined 
through in Situ Glycan Imaging. J Proteome Res 17, 3454-3462. 
White, D.L., Thrift, A.P., Kanwal, F., Davila, J., and El-Serag, H.B. (2017). Incidence of Hepatocellular 
Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology 152, 812-820 
e815. 
Wu, W., Li, J., Liu, Y., Zhang, C., Meng, X., and Zhou, Z. (2012). Comparative proteomic studies of serum 
from patients with hepatocellular carcinoma. J Invest Surg 25, 37-42. 
Wu, Y., Mechref, Y., Klouckova, I., Mayampurath, A., Novotny, M.V., and Tang, H. (2010). Mapping site-
specific protein N-glycosylations through liquid chromatography/mass spectrometry and 
targeted tandem mass spectrometry. Rapid Commun Mass Spectrom 24, 965-972. 
Au
tho
r M
an
us
cri
pt
Xu, Z., Zhou, X., Lu, H., Wu, N., Zhao, H., Zhang, L., Zhang, W., Liang, Y.L., Wang, L., Liu, Y., Yang, P., and 
Zha, X. (2007). Comparative glycoproteomics based on lectins affinity capture of N-linked 
glycoproteins from human Chang liver cells and MHCC97-H cells. Proteomics 7, 2358-2370. 
Yamamoto, K., Imamura, H., Matsuyama, Y., Kume, Y., Ikeda, H., Norman, G.L., Shums, Z., Aoki, T., 
Hasegawa, K., Beck, Y., Sugawara, Y., and Kokudo, N. (2010). AFP, AFP-L3, DCP, and GP73 as 
markers for monitoring treatment response and recurrence and as surrogate markers of 
clinicopathological variables of HCC. J Gastroenterol 45, 1272-1282. 
Yamasaki, K., Tateyama, M., Abiru, S., Komori, A., Nagaoka, S., Saeki, A., Hashimoto, S., Sasaki, R., Bekki, 
S., Kugiyama, Y., Miyazoe, Y., Kuno, A., Korenaga, M., Togayachi, A., Ocho, M., Mizokami, M., 
Narimatsu, H., and Yatsuhashi, H. (2014). Elevated serum levels of Wisteria floribunda 
agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular 
carcinoma in hepatitis C patients. Hepatology 60, 1563-1570. 
Yang, G., Cui, T., Wang, Y., Sun, S., Ma, T., Wang, T., Chen, Q., and Li, Z. (2013). Selective isolation and 
analysis of glycoprotein fractions and their glycomes from hepatocellular carcinoma sera. 
Proteomics 13, 1481-1498. 
Yang, M.H., Tyan, Y.C., Jong, S.B., Huang, Y.F., Liao, P.C., and Wang, M.C. (2007). Identification of human 
hepatocellular carcinoma-related proteins by proteomic approaches. Anal Bioanal Chem 388, 
637-643. 
Yang, W., Shah, P., Hu, Y., Toghi Eshghi, S., Sun, S., Liu, Y., and Zhang, H. (2017). Comparison of 
Enrichment Methods for Intact N- and O-Linked Glycopeptides Using Strong Anion Exchange and 
Hydrophilic Interaction Liquid Chromatography. Anal Chem 89, 11193-11197. 
Yang, Z., Harris, L.E., Palmer-Toy, D.E., and Hancock, W.S. (2006). Multilectin affinity chromatography for 
characterization of multiple glycoprotein biomarker candidates in serum from breast cancer 
patients. Clin Chem 52, 1897-1905. 
Yin, H., An, M., So, P.K., Wong, M.Y., Lubman, D.M., and Yao, Z. (2018). The analysis of alpha-1-
antitrypsin glycosylation with direct LC-MS/MS. Electrophoresis 39, 2351-2361. 
Yin, H., Lin, Z., Nie, S., Wu, J., Tan, Z., Zhu, J., Dai, J., Feng, Z., Marrero, J., and Lubman, D.M. (2014). 
Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular 
carcinoma. J Proteome Res 13, 2887-2896. 
Yin, H., Tan, Z., Wu, J., Zhu, J., Shedden, K.A., Marrero, J., and Lubman, D.M. (2015). Mass-Selected Site-
Specific Core-Fucosylation of Serum Proteins in Hepatocellular Carcinoma. J Proteome Res 14, 
4876-4884. 
Young, J.B., and Li, L. (2006). An impulse-driven liquid-droplet deposition interface for combining LC with 
MALDI MS and MS/MS. J Am Soc Mass Spectrom 17, 325-334. 
Yu, Q., Wang, B., Chen, Z., Urabe, G., Glover, M.S., Shi, X., Guo, L.W., Kent, K.C., and Li, L. (2017). 
Electron-Transfer/Higher-Energy Collision Dissociation (EThcD)-Enabled Intact 
Glycopeptide/Glycoproteome Characterization. J Am Soc Mass Spectrom 28, 1751-1764. 
Yuan, W., Sanda, M., Wu, J., Koomen, J., and Goldman, R. (2015). Quantitative analysis of 
immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease. J 
Proteomics 116, 24-33. 
Zekri, A.R., Bahnassy, A.A., Alam El-Din, H.M., Morsy, H.M., Shaarawy, S., Moharram, N.Z., and Daoud, 
S.S. (2011). Serum levels of beta-catenin as a potential marker for genotype 4/hepatitis C-
associated hepatocellular carcinoma. Oncol Rep 26, 825-831. 
Zhang, H. (2007). Glycoproteomics using chemical immobilization. Curr Protoc Protein Sci Chapter 24, 
Unit 24 23. 
Zhang, S., Jiang, K., Zhang, Q., Guo, K., and Liu, Y. (2015a). Serum fucosylated paraoxonase 1 as a 
potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA 
Index. Glycoconj J 32, 119-125. 
Au
tho
r M
an
us
cri
pt
Zhang, S., Shu, H., Luo, K., Kang, X., Zhang, Y., Lu, H., and Liu, Y. (2011). N-linked glycan changes of serum 
haptoglobin beta chain in liver disease patients. Mol Biosyst 7, 1621-1628. 
Zhang, Y., Zhu, J., Yin, H., Marrero, J., Zhang, X.X., and Lubman, D.M. (2015b). ESI-LC-MS Method for 
Haptoglobin Fucosylation Analysis in Hepatocellular Carcinoma and Liver Cirrhosis. J Proteome 
Res 14, 5388-5395. 
Zhang, Z., Zhang, Y., Wang, Y., Xu, L., and Xu, W. (2016). Alpha-fetoprotein-L3 and Golgi protein 73 may 
serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular 
carcinoma. Onco Targets Ther 9, 123-129. 
Zhao, J., Qiu, W., Simeone, D.M., and Lubman, D.M. (2007). N-linked glycosylation profiling of pancreatic 
cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J 
Proteome Res 6, 1126-1138. 
Zhao, J., Simeone, D.M., Heidt, D., Anderson, M.A., and Lubman, D.M. (2006). Comparative serum 
glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: 
application to pancreatic cancer serum. J Proteome Res 5, 1792-1802. 
Zhao, Y., Jia, W., Wang, J., Ying, W., Zhang, Y., and Qian, X. (2011). Fragmentation and site-specific 
quantification of core fucosylated glycoprotein by multiple reaction monitoring-mass 
spectrometry. Anal Chem 83, 8802-8809. 
Zhao, Y., Zhang, L., Huo, L., Pei, L., Li, Q., Li, H., and Jin, L. (2018). Clinical significance of fucosylated GP73 
in the differential diagnosis of hepatocellular carcinoma. Int J Biol Markers, 1724600818796646. 
Zhong, X., Chen, Z., Snovida, S., Liu, Y., Rogers, J.C., and Li, L. (2015). Capillary Electrophoresis-
Electrospray Ionization-Mass Spectrometry for Quantitative Analysis of Glycans Labeled with 
Multiplex Carbonyl-Reactive Tandem Mass Tags. Anal Chem 87, 6527-6534. 
Zhu, J., Chen, Z., Zhang, J., An, M., Wu, J., Yu, Q., Skilton, S.J., Bern, M., Sen, K.I., Li, L., and Lubman, D.M. 
(2018). Differential quantitative determination of site-specific intact N-glycopeptides in serum 
haptoglobin between hepatocellular carcinoma and cirrhosis using LC-EThcD-MS/MS. (in 
revision). 
Zhu, J., Lin, Z., Wu, J., Yin, H., Dai, J., Feng, Z., Marrero, J., and Lubman, D.M. (2014). Analysis of serum 
haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J 
Proteome Res 13, 2986-2997. 
Zhu, J., Wu, J., Yin, H., Marrero, J., and Lubman, D.M. (2015). Mass Spectrometric N-Glycan Analysis of 
Haptoglobin from Patient Serum Samples Using a 96-Well Plate Format. J Proteome Res 14, 
4932-4939. 
 
 
 
 
 
 
 
Au
tho
r M
an
us
cri
pt
Figure Captions 
Figure 1. General lectin FLISA methodology for the measurement of glycoproteins with specific 
glycan motif. The method involves an antibody to selectively capture the target glycoprotein 
from biological samples and then a fluorophore-conjugated lectin is used to detect the glycan 
motif with the appropriate structural moiety. The antibody’s glycans are oxidized so they will not 
interfere with the analysis.  
 
Figure 2. (a) Workflow of N-glycan profiling of haptoglobin and fucosylation changes between 
HCC and liver cirrhosis of the three most common etiologies, infection with HBV or HCV, and 
heavy alcohol consumption (ALD). (b) MALDI-QIT-MS spectra showing the difference of 
fucosylation in tri- and tetra-antennary N-glycans of haptoglobin between HCC and cirrhosis in 
relation to the etiology, HBV (A), HCV (B), and ALD (C), respectively. The bifucosylated tetra-
antennary (m/z 3316.69) glycan was predominantly present in HCC samples but not in liver 
cirrhosis. The tetra-antennary glycans were highly elevated in HBV- and ALD-related HCC 
compared with the corresponding levels in cirrhosis; however, no significant difference in tetra-
antennary glycans was observed between HCV-related HCC and cirrhosis. The elevated 
presence of fucosylated tetra-antennary glycans in HCC samples compared to that in cirrhosis 
of each etiology is highlighted with a red rectangle. Reprinted with permission from Ref [J. 
Proteome Res. 2014, 13, 2986−2997]. 
 
Figure 3. EIC of biantennary monosialylated branch-fucosylated glycan linkage isomers derived 
from (a) cirrhotic and (b) HCC patients. (c) MS/MS interpretation of biantennary monosialylated 
branch-fucosylated glycan. (d) Unsupervised PCA plot of the glycans that were quantitatively 
determined by C18-LC-MS/MS analysis. Reprinted with permission from Ref [Electrophoresis 
2017, 38, 2160–2167].  
 
Figure 4. IMS profiles of glycan ions (A) [S1H5N4 + 3Na]3+ and (B) [S1F1H5N4 + 3Na]3+ 
glycans showing both conformational and intensity differences with respect to disease state. 
Note that in the case of S1H5N4, the disease states exhibit lower overall intensities than the 
healthy state, while S1F1H5N4 shows higher overall drift time intensities in the case of diseased 
states than in the healthy state. This might be due to increased fucosylation of glycans with 
cancer and cirrhosis. Reprinted with permission from Ref [J. Proteome Res. 2012, 11, 
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576−585]. 
 
Figure 5. Workflow for screening of changes in site-specific core-fucosylation (CF) of serum 
proteins in early stage HCC with different etiologies. The methods involve depletion of high 
abundance proteins, trypsin digestion of medium-to-low abundance proteins into peptides, 
iTRAQ labeling, and Lens culinaris Agglutinin (LCA) enrichment of CF peptides, followed by 
endoglycosidase F3 digestion before mass spectrometry analysis. 1300 CF peptides from 613 
CF proteins were identified from patient sera, where 20 and 26 CF peptides were differentially 
expressed in alcohol (ALD)-related HCC samples compared with ALD-related cirrhosis samples 
and HCV-related HCC compared with HCV-related cirrhosis samples. Reprinted with permission 
from Ref [J. Proteome Res. 2015, 14, 4876−4884]. 
 
Figure 6. Examples of (A) the stepped-energy HCD MS/MS collision for an intact glycopeptide, 
reprinted with permission from Ref [Nature Commun 2017, 8: 438] and (B) the EThcD MS/MS 
collision of N-glycopeptide TVLTPATNHMGNVTFTIPANR, reprinted with permission from Ref 
[J. Am. Soc. Mass Spectrom. (2017) 28:1751-1764] 
 
Figure 7. A scheme which shows the process for identifying aberrantly glycosylated biomarkers 
using the lectin-coupled MRM-based approach. Reprinted with permission from Ref [J. 
Proteomics 2012, 75, 5507-5515]. 
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